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Natural Killer (NK) cells are innate lymphocytes that play an essential role in 
host defence against viral infection and tumours. The activation and function 
of NK cells is regulated by cytokines, in particular IL-15, which promotes their 
differentiation, survival and activation. IL-10 is a potent immunosuppressive 
cytokine; however, some studies report immunostimulatory activity towards 
NK cells.  The aim of this study was to investigate the immunomodulatory 
effects of IL-10 on NK cell activity. Using an in vitro system of primary human 
NK cells, the effect of IL-10 stimulation on key NK cell activating pathways, 
such as cytotoxicity, receptor expression and proliferation was explored. IL-
10 stimulation of NK cells enhanced granzyme B expression and NK cell 
cytotoxicity in a STAT3-dependent manner. Unlike the prototypical NK cell 
activator, IL-15, IL-10 stimulation did not alter the expression of NK cell 
activating receptors, induce proliferation or activate the mTOR pathway.  The 
immunosuppressive cytokine TGF-β inhibits IL-15-mediated NK cell activation 
by inhibiting mTOR signalling.  Interestingly, although this study does not 
show IL-10 activation of mTOR signalling, IL-10 mediated NK cell activation 
was susceptible to TGF-β-mediated inhibition. Moreover, this TGF-β mediated 
inhibition was independent of STAT3 signalling, suggesting the involvement 
of other, as yet undefined pathways. This study highlights distinct pathways 
of NK cell activation by IL-15 and IL-10, and defines an IL-10 mediated, 
mTOR-independent, activation pathway. Observations in this study suggest 
that the complex mechanisms leading to activation of NK cells can be induced 
independently of one another, providing further insight into immune cell 
regulation.  
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Chapter 1 
Introduction 
1.1 The immune system – an overview 
The immune system is a highly complex network that protects the host from 
infection and disease. Defence against infection comprises physical barriers 
(e.g. epithelial cell barriers, ciliated cells and mucus layers) as well as cells 
and proteins of the immune system, including soluble proteins (e.g. 
complement proteins, antibodies and defensins) and cellular responses 
(Chaplin, 2010, Turvey and Broide, 2010).  
Immune responses are divided into two arms, innate immunity, 
providing a first line of defence, and adaptive immunity that provides an 
antigen specific response.  A key defining factor between these two immune 
arms is the expression of specific antigen receptors. Innate immune function 
is regulated by the expression of germline encoded receptors, whereas 
adaptive immune responses require the expression of antigen-specific 
receptors that have undergone somatic rearrangement during development 
(hence the term, adaptive) (Bonilla and Oettgen, 2010).  
Haematopoietic stem cells (HSCs) are the precursors of all immune 
cells, giving rise to two distinct lineages of cells, labelled as myeloid and 
lymphoid cells. Generally speaking, myeloid cells make up the innate immune 
system and lymphoid cells make up the adaptive immune system, with T and 
B lymphocytes expressing antigen-specific receptors, namely T-cell receptors 
(TCR) and B-cell receptors (BCR), respectively. The exception to this being 
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natural killer (NK) lymphocytes and the related, recently described innate 
lymphoid cells (ILC). Although these cells are derived from common lymphoid 
progenitor (CLP) cells, they do not express antigen-specific receptors and 
instead act as part of the innate immune response (Vivier et al., 2018). 
Innate and adaptive immunity do not work in isolation but instead 
collaborate extensively to provide the appropriate immune response. Immune 
regulation is achieved by a balance of mechanisms that are used to induce an 
immune response, but also ones to limit that response. This tight regulation is 
essential to prevent uncontrolled inflammation that can lead to tissue damage 
and autoinflammatory or autoimmune diseases. 
 
1.1.1 The innate immune system  
The innate immune system acts as a first line of defence, providing rapid 
responses to control infection whilst the adaptive immune response develops. 
Innate immune cells express a variety of germline encoded pattern recognition 
receptors (PRR) to detect invading pathogens. Four classes of PRRs are 
found in humans, the transmembrane receptors toll-like receptors (TLR) and 
C-type lectin receptors (CLR), and the cytoplasmic receptors NOD-like 
receptors (NLR) and retinoic acid-inducible gene I like receptors (RLR). Each 
of the PRRs recognise distinct structural motifs expressed by pathogens 
(pathogen-associated molecular patterns [PAMP]) or released from damaged 
cells (damage-associated molecular patterns [DAMP]) (Takeuchi and Akira, 
2010). Binding to these receptors stimulates an inflammatory response to 
control the infection, but also serves to initiate an adaptive immune response. 
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A key player in the initiation of the adaptive immune response are dendritic 
cells (DC). DCs are professional antigen presenting cells (APC) that detect 
pathogens, process their antigens and load them onto major histocompatibility 
complex molecules (MHC) that are then presented to T cells to induce an 
antigen specific response. DCs are innate phagocytes that process 
intracellular and exogenous antigens and present them on MHC I and MHC II 
molecules, respectively. Exposure to inflammatory cytokines (such as at sites 
of infection) induce the differentiation and maturation of DCs. Subsequently, 
DCs upregulate chemokine receptors that enables them to migrate to lymph 
nodes where they interact with T cells. In addition to TCR/MHC binding, DCs 
also express co-stimulatory molecules, such as CD80 and CD86, that are 
required for T cell differentiation and activation. This interaction is a key factor 
in priming adaptive immune response, therefore, DCs are positioned at the 
interface of innate and adaptive immunity (Lee and Iwasaki, 2007).  
 
1.1.2 The adaptive immune system 
The adaptive immune system is comprised of B and T lymphocytes (B cells 
and T cells) which mediate humoral and cell-mediated immunity, respectively. 
Both cell types express individual antigen receptors (BCR and TCR, 
respectively) that undergo somatic rearrangement during development, 
resulting in a highly diverse repertoire of receptors greatly enhancing the 
specificity of antigen recognition  (Bonilla and Oettgen, 2010). B cells secrete 
antibody to affect humoral immunity. This includes the neutralisation of toxins, 
the coating of pathogens or infected cells for recognition by cells bearing Fc 
receptors (FCRs) (opsonisation) and the fixation of the complement cascade 
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(Hoffman et al., 2016). Mature T cells are generally grouped based on their 
expression of CD4 and CD8; CD4+ T cells being T helper cells and CD8+ T 
cells being cytotoxic T cells (CTLs). Once activated, CTLs mediate the killing 
of target cells whereas T helper cells differentiate into either Th1 or Th2 cells 
that have distinct differences in cytokine production (Andersen et al., 2006). 
The major effectors of a Th1 response are interferon-gamma (IFN-γ) and 
tumour necrosis factor (TNF), which promote T cell mediated immunity, 
whereas interleukin (IL)-4, IL-5, IL-6, IL-9, IL-10 and IL-13 are all Th2 
cytokines that promote humoral responses (Romagnani, 2000). However, 
there is extensive crosstalk between these systems that ensure efficient 
immune protection.  
 
1.2 Natural Killer cells 
NK cells are a critical component of the innate immune system that play an 
essential role in the defence against transformed and virally infected cells. 
Accordingly, patients with NK cell deficiencies have increased susceptibility to 
viral infections and cancers. Patients with NK cell deficiencies are particularly 
susceptible to herpesvirus infection, importantly, several deaths have been 
reported in these patients as a result of severe infections with varicella zoster 
virus (VZV) infection, cytomegalovirus (CMV) infection and Epstein-Barr virus 
(EBV). Increased incidences of virus related cancers and leukaemias are also 
reported in this population. Furthermore, impaired NK function contributes to 
the pathogenesis of several primary immunodeficiencies (PID) (Orange, 2013, 
Mace and Orange, 2016).  
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 NK cells cells were first identified as cells that displayed “natural 
cytotoxic reactivity” against a variety of tumours. These spontaneous killer 
cells had the morphology of small lymphocytes but lacked both T and B 
lymphocyte markers, leading to the classification of a third lymphocyte (B. et 
al., 1975a, B. et al., 1975b, R. et al., 1975). As well as lacking T and B cell 
antigen receptors, human NK cells are identified by the surface expression of 












Many reports suggest CD56 expression is linked 
to differentiation, with the CD56
bright
 cells being a precursor to the CD56
dim
, 
but this has been contested and the developmental relationship between 
these subgroups remains unclear (Domaica et al., 2012, Michel et al., 2016, 





 populations are both present in secondary lymph organs (SLO) and 
the periphery and appear to have different roles. CD56
dim
 account for 
approximately 90 % of circulating NK cells, are highly cytotoxic and produce 
relatively low levels of cytokine, whereas CD56
bright
 account for approximately 
10% of circulating NK cells, are less cytotoxic but produce an abundance of 
cytokines. In contrast to the circulating population, approximately 90% of the 
NK cells in SLO are CD56
bright
 and 10% are CD56
dim
 (Caligiuri, 2008a) (Poli et 
al., 2009). The ability of CD56
bright
 NK cells to make large amounts of IFN-γ 
and traffic to the lymph nodes is believed to be a mechanism by which NK 
cells promote Th1 responses and enhance T cell mediated immunity (Martín-
Fontecha et al., 2004). The distinct roles of these subsets are apparent in 
resting NK cells and are accompanied by differential expression of receptors 
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and cytolytic proteins; however, upon activation, CD56
bright
 cells also acquire 
cytotoxicity and display anti-tumour activity (Michel et al., 2016, Wagner et al., 
2017). 
 
1.2.1 NK cell receptors 
NK cells show some similarity to CTLs in their ability to kill target cells via 
granule mediated cytotoxicity and to secrete pro-inflammatory cytokines, such 
as IFN-γ (Paust et al., 2010). In contrast to antigen specific T cell activation, 
NK cells are regulated by a multitude of germline encoded activating and 
inhibiting receptors (Lanier, 2005). Our current understanding of NK cell 
receptors stems from the ‘missing self-hypothesis’. Based on the discovery 
that MHC deficient murine lymphoma cell lines were susceptible to NK cell 
mediated apoptosis, Karre et al. proposed that NK cells could discriminate 
between ‘self’ and ‘missing-self’ cells on the basis of MHC expression 
(Ljunggren and Kärre, 1990, Kärre et al., 1986). Since then, a plethora of NK 
cell activating and inhibiting receptors have been discovered (Pegram et al., 
2011). Ultimately, NK cell function is determined by the balance of signals 
received through these receptors (Culley et al., 2009) (Figure 1). 
 - 19 - 
 
Figure 1: NK cell activation. 
The activation of NK cells is governed by an array of activating and inhibitory 
receptors. The integration of signals through these activating and inhibitory receptors 
determines the activation and subsequent functions of NK cells. Figure adapted from 
(Lanier, 2005).  
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1.2.1.1 NK cell inhibitory receptors 
As cells of the innate immune system, NK cells respond rapidly in response 
to target recognition. Therefore, the activation of NK cells is tightly regulated 
by the expression of inhibitory receptors. Under steady state conditions, 
inhibitory receptor signalling prevents NK cells from eliciting unsolicited 
cytotoxicity, thereby protecting healthy cells and preventing autoimmune 
activity. The expression of inhibitory receptors is essential to educate NK cells 
(discussed in section 1.2.2) and allow for appropriate target recognition 
(Höglund and Brodin, 2010). The majority of inhibitory receptors recognise 
healthy ‘self’ cells through the expression of MHC class I molecules that are 
expressed by most healthy cells (Shifrin et al., 2014), notable exceptions 
being erythrocytes and neurons. Killer Ig-like receptors (KIRs) and the 
CD94/NKG2A heterodimer inhibit NK cell activation through the recognition of 
classical MHC I molecules (human leukocyte antigen [HLA]-A, B and C) and 
non-classical MHC I molecules (HLA-E), respectively (Table 1) (Braud et al., 
1998, Lanier, 2005, Moretta and Moretta, 2004). Inhibitory KIRs and 
CD94/NKG2A share the common feature of an immunoreceptor tyrosine 
inhibition motifs (ITIMs) located in the cytoplasmic tail. Ligand binding induces 
the phosphorylation of ITIMs, which in turn phosphorylates SH2-domain-
containing protein tyrosine phosphatase 1 (SHP-1) and blocks activation 
signals (Pegram et al., 2011). Additionally, NK cell inhibitory receptors that do 
not recognise MHC molecules have been identified. CD96 and T cell 
immunoreceptor with immunoglobulin and ITIM domains (TIGIT), have both 
been shown to inhibit NK cell function through binding to nectin and nectin-
like proteins (Martinet and Smyth, 2015). Although ITIMs have been identified 
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in the cytoplasmic tails of these receptors, less is known about the signalling 
mechanisms (Martinet and Smyth, 2015). 
Expression of MHC I molecules provides protection from NK cells, 
conversely, T cells recognise antigens presented on MHC molecules. In an 
attempt to evade T cell recognition, transformed and virally infected cells 
frequently downregulate expression of MHC I (Bukur et al., 2012). For 
example, herpesviruses encode multiple proteins to inhibit antigen 
presentation by MHC class I (Hewitt, 2003, Lanier, 2008). In line with the 
missing self-hypothesis, this reduction or absence of MHC I expression would 
render them susceptible to NK cell mediated apoptosis (Ljunggren and Kärre, 
1990).  
 
1.2.1.2 Activating Receptors   
NK cell recognition of target cells requires the engagement of activating 
receptors located on the plasma membrane of NK cells. Tumour cells and 
virally infected cells express a multitude of proteins in response to cellular 
stress that bind these receptors and subsequently activate NK cells (Chan et 
al., 2014). Multiple activating NK cell receptors have been identified in 
humans, including 2B4, Natural killer group 2 member D (NKG2D), DNAX 
accessory molecule 1 (DNAM1), and the natural cytotoxicity receptors (NCRs) 
NKp30, NKp44 and NKp46 (Chester et al., 2015, Pegram et al., 2011) (Table 
1). Additionally, activating isoforms of KIRs, that also recognise MHC 
molecules, are also expressed by NK cells. Similar to the cytoplasmic ITIMs 
located on inhibitory receptors, most activating receptors signal via 
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immunoreceptor tyrosine based activation motifs (ITAMs); however, activating 
receptors do not encode these regions but rather associate with adaptor 
proteins that contain an ITAM (Moretta and Moretta, 2004). TCRζ, FcRγ and 
DAP-12 are ITAM bearing adaptor proteins that form complexes 
(homo/heterodimers) and associate with the cytoplasmic regions of specific 
receptors to transduce NK cell activating receptor signalling. Some activating 
receptors induce downstream signalling independently of ITAMs, for example, 
NKG2D associates with the transmembrane molecule DAP10 and 2B4 
contains an immunoreceptor tyrosine-based switch motif (ITSM) (Pegram et 
al., 2011, Long et al., 2013). 
In addition to activating receptors that detect target cell expressed 
ligands, NK cells also express CD16 (FcγRIII),  a low affinity receptor for IgG;  
antibody dependent cellular cytotoxicity (ADCC) is triggered when CD16 binds 
to the Fc regions of clustered IgG antibodies on opsonised targets to induce 
cell cytotoxicity (Bryceson et al., 2006). CD16 signalling is also important in 
the context of therapeutic antibodies. For example, NK cell mediated ADCC 
is known to contribute to the actions of monoclonal antibodies used in the 
treatment of some cancers (Ochoa et al., 2017). NK cells do not possess a 
dominant activation receptor (e.g. analogous to the TCR or BCR), and 
subsequently require synergistic co-signalling through multiple receptors to 
achieve activation. With the exception of CD16 (which mediates ADCC rather 
than ‘natural killing’), engagement of no single receptor has been found to 
induce degranulation and so all are described to be ‘co-activation’ receptors 
(Long et al., 2013). Moreover, the balance of NK cell activating/inhibitory 
signals is further regulated by a ‘threshold’ of MHC I expression, meaning that 
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small changes in the expression of ligands can drastically alter NK cell 
responses. For instance, tumour cell expression of MHC I below the threshold 
results in NK cell activation, whereas tumour cells with MHC I expression 
above this threshold did not activate NK cells (Holmes et al., 2011). 
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Table 1: NK cell receptors 
Activatory and inhibitory NK cell receptors and their reported ligands. Table adapted 
from (Long et al., 2013, Pegram et al., 2011, Martinet and Smyth, 2015).  
AICL: activation-induced C-type lectin; BAG6: BCL2-associated athanogene 6; BAT-
3; HLA-B-associated transcript 3; DNAM1: DNAX accessory molecule 1; HA: 
hemagglutinin; HLA: human leukocyte antigen; HSPG: heparin sulphate 
proteoglycan; MICA/B: MHC class 1 chain related protein A/B; MHC: major 
histocompatibility complex; NKG2D: Natural killer group 2 member D; TIGIT: T cell 
immunoreceptor with immunoglobulin and ITIM domains; ULBP: UL16 binding 
protein. 
 
NK cell receptors Ligand Activating/Inhibitiory
Natural cytotoxicity receptors (NCRs)
NKp30 B7-H6/BAT3/BAG6 Activating
NKp44 Viral HA Activating
NKp46 Viral HA, HSPG Activating
NKp80 AICL Activating
DNAM1 CD112 or CD155 Activating
NKG2D MICA/B, ULBP 1-4 Activating
2B4 CD48 Activating
Killer Ig-like receptors (KIRs)
KIR2DL4














CD94/NKG2A MHC I (HLA-E) Inhibitory
TIGIT CD155 Inhibitory
CD96 CD155 Inhibitory
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1.2.2 NK cell education  
The expression of NK cell receptors is highly heterogeneous and results in 
many phenotypically distinct mature NK cells, including NK cells that are 
hyporesponsive. Mostly, NK cells express one KIR providing efficient 
detection of cells that lose the corresponding MHC class I ligand (e.g. as a 
result of natural selection by T cells). However, a small population of NK cells 
do not express KIRs, or express KIRs that do not have a corresponding MHC 
ligand. NK cells lacking KIRs (or lacking engageable KIRs) are potentially 
dangerous, as they cannot be inhibited by MHC class I on healthy cells; these 
NK cells are rendered hyporesponsive (Elliott and Yokoyama, 2011, Höglund 
and Brodin, 2010, Anfossi et al., 2006). This hyporesponsive state is a direct 
result of being ‘uneducated’. NK cell education is the term used to explain the 
paradoxical hypothesis that NK cells require inhibitory signalling to achieve 
effector functions and self-tolerance. During development, engagement of 
inhibitory KIRs educates the NK cells and is an important step to gain effector 
functions. The exact mechanism of how NK cells become educated is a 
debated topic and there are currently three proposed models. The ‘arming’ 
model proposes that NK cells become armed through the ligation of KIRS and 
subsequent signalling via the inhibitory signalling pathway. The ‘disarming’ 
model proposes that NK cells are readily reactive and require inhibitory KIR 
engagement to prevent sustained activation, failure to engage inhibitory 
receptors ‘disarms’ the NK cells by activation-induced anergy. Lastly, the 
‘rheostat’ model proposes that NK cell reactivity is determined by the 
expression of KIRs and the affinity and availability of ligands, with higher 
expression of inhibitory KIRs resulting in better education of NK cells (Orr and 
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Lanier, 2010, Boudreau and Hsu, 2018). More recently, a role for NKG2A and 
the non-MHC-I receptor in NK cell education has emerged, with co-expression 
of receptors resulting in better responsiveness of NK cells (He and Tian, 
2017). Unlike clonal deletion of autoreactive T-cells, uneducated NK cells 
remain in circulation in a hyporesponsive state. These uneducated NK cells 
can subsequently be activated by pro-inflammatory cytokines (Holmes et al., 
2014). While educated NK cells are essential to recognise target MHC I 
deficient cells, the activation of uneducated NK cells is beneficial against some 
infections and tumours (Orr et al., 2010, Tu et al., 2016). Cytokine activation 
of these KIR negative, hyporesponsive NK cells enables them to attack target 
cells without being restricted by MHC I expression. However, these activated, 
uneducated NK cells are also a potential source of tissue damage, as they 
might attack MHC class I expressing healthy cells.  
 
1.3 Mechanisms of NK cell cytotoxicity 
The primary killing mechanism of NK cells is the exocytosis of lytic granules 
(degranulation) across an immunological synapse (IS), at the interface of the 
NK and the target cell (Figure 2). Upon target recognition and NK cell 
activation, ligation of integrins such as LFA-1 initiates the formation of the 
highly organised IS. Integrins are localised to the peripheral supramolecular 
activation cluster (pSMAC), whilst activating NK cell receptors localise to the 
central supramolecular activation cluster (cSMAC). Integrin signalling results 
in the reorganisation of F-actin and the polarisation of the microtubule 
organisation centre (MTOC) towards the IS. Lytic granules are then able to 
move along the microtubules and translocate to the MTOC. Once located at 
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the immunological synapse, the lytic granules navigate through the dense 
actin network and fuse with the plasma membrane to release their contents 
across the synapse; a regulated exocytic mechanism (Krzewski and Coligan, 
2012, Mace et al., 2014). Perforin is essential to enable entry of granzymes 
into the target cell. Perforin monomers oligomerises on the surface of the 
target cell and create pores through which the granzymes can diffuse (Lopez 
et al., 2013) (Figure 2). Five granzymes have been identified in humans (A, B, 
H, K and M), of which granzyme B is the most abundant and well-studied. The 
granzymes are a family of serine proteases and, in the case of granzyme B, 
the specificity resembles that of caspases, cleaving on the C-terminal side of 
aspartate residues (Chowdhury and Lieberman, 2008). Granzyme B, a potent 
pro-apoptotic enzyme, induces apoptosis through caspase-dependent and 
caspase-independent pathways. The primary mechanism of human granzyme 
B mediated cell death is through cleavage of the pro-apoptotic protein BID, 
resulting in mitochondrial disruption, cytochrome c release and subsequent 
apoptosis (Pinkoski et al., 2001, Cullen and Martin, 2008). Additionally, 
granzyme B can directly cleave caspases and caspase substrates, resulting 
in rapid apoptosis of the target cell (e.g. within minutes) (Scott et al., 2010, 
Voskoboinik et al., 2015, Martinvalet, 2019). Recent studies have also 
described a role for reactive oxygen species (ROS) in granzyme B induced 
apoptosis (Jacquemin et al., 2015, Chiusolo et al., 2017). Granzyme B was 
shown to enter intact mitochondria via transport proteins and cleave subunits 
in the electron transport chain (ETC) complex I that resulted in impaired 
mitochondrial respiration and rapid ROS production. Moreover, inhibiting entry 
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to the mitochondria severely reduced the cytotoxic activity of granzyme B 




Figure 2: Activatory immunological synapse 
Schematic overview of the immunological synapse between NK cell and target cells 
during degranulation. Upon activation, NK cells undergo cytoskeletal rearrangement 
that allows the secretion of lytic granules across the immunological synapse in a 
polarised manner. Once secreted, granzymes enter the target cells through perforin 
formed pores and induce apoptosis through several different pathways. Figure 
adapted from (Krzewski and Coligan, 2012, Smyth et al., 2005). 
cSMAC: central supramolecular activation cluster; MTOC: microtubule organisation 
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1.4 Lytic granules 
The lytic granules are specialised secretory lysosomes located within the NK 
cell cytoplasm that contain the major cytotoxic proteins perforin and 
granzymes. Due to the highly cytotoxic activity of the contents, the 
organisation and environment within the lytic granules inhibits the activity of 
the proteins to provide safe storage of the potentially lethal molecules. For 
instance, proteoglycans associate with perforin and granzymes in the core of 
the lytic granules to prevent diffusion of the proteins into the cell. Additionally, 
the luminal environment of the lytic granules is acidic (pH5.5) to inhibit the 
proteins that are optimally active at neutral pH (Anthony et al., 2010). Other 
proteins located in the lytic granules include cathepsins to proteolytically 
activate granzyme and perforin, and the pro-inflammatory molecule granulysin 
(Krzewski and Coligan, 2012). Lysosome-associated membrane protein 1 
(LAMP-1/CD107a) is the most abundant protein located on the lytic granule 
membrane, and is therefore used as a marker of degranulation. The 
expression of LAMP-1 appears to be important in perforin recruitment to lytic 
granules and granule motility. LAMP-1 deficient cells display reduced perforin 
in the lytic granules, reduced motility of granules and ultimately reduced 
cytotoxicity (Krzewski et al., 2013).  
 In addition to granule dependent cell death, NK cells can induce target 
cell death via death receptor pathways. The NK cell expression of TNF related 
apoptosis-inducing ligand (TRAIL) and FAS ligand (FasL) mediate cell death 
of target cells that express the cognate receptors, ligation of these receptors 
recruit death domains and subsequently induces apoptosis via the caspase 
cascade (Kayagaki et al., 1999, Arase et al., 1995, Wallin et al., 2003).  
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1.5 Pro-inflammatory cytokine secretion 
The second effector function of NK cells is the secretion of the pro-
inflammatory cytokines such as IFN-γ, tumour necrosis factor (TNF) and 
granulocyte-macrophage colony stimulating factor (GM-CSF) (Fehniger et al., 
1999). In addition to activating receptor ligation, NK cell cytokine production 
can be induced through cytokine receptor stimulation. To enable rapid 
production of cytokines, NK cells constitutively express receptors for cytokines 
such as IL-12, IL-15 and IL-18 (Fehniger et al., 1999, Vivier et al., 2011, 
Holmes et al., 2014). These NK cell-derived cytokines have several 
immunomodulatory functions that contribute towards pathogen clearance and 
activation of the adaptive immune response.  
 
1.5.1 infection 
Upon pathogen detection, immune cells secrete a plethora of inflammatory 
cytokines that can induce NK cell cytokine secretion. For instance, the most 
abundantly expressed cytokines in response to viral infections are type 1 IFNs 
(IFN-α/IFN-β). Type 1 IFNs activate NK cells to secrete IFN-γ that helps to 
resolve viral infection (Christine A. Biron et al., 1999) (Mack et al., 2011, 
Martinez et al., 2008). Other cytokines such as IL-12 and IL-15 are also 
important mediators of NK cell function in viral infections. Type 1 IFNs induce 
the expression of IL-15 which in turn promotes NK cell survival, whereas IL-
12 is a potent inducer of IFN-γ (Nguyen et al., 2002, Baranek et al., 2012, 
Orange and Biron, 1996). Furthermore, viruses can directly induce IFN-γ and 
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TNF-α from NK cells through TLR stimulation (Adib-Conquy et al., 2014) 
(Sivori et al., 2004).  
1.5.2 Adaptive immune response 
IFN-γ is essential to help prime adaptive immune responses, in particular, NK 
cell-derived IFN-γ is essential for Th1 polarisation. In lymph nodes, activated 
NK cells produce IFN-γ, which in turn stimulated the production of IL-12 from 
DCs that promotes Th1 polarisation (Martín-Fontecha et al., 2004). At sites of 
inflammation, NK cell-derived IFN-γ enhances the expression of MHC class I 
and II and promotes the differentiation of monocytes into DCs (Goldszmid et 
al., 2012). Moreover, DCs interact with NK cells via surface receptors, to 
induce the secretion of IFN-γ and TNF-α and promote DC maturation (Vitale 
et al., 2005). 
 
1.5.3 Tumour immune surveillance 
 NK cell-derived cytokines also have an important function in tumour immune 
surveillance. As tumour cells are ‘self’ cells, they do not express PAMPs and 
thus do not trigger DCs via PRRs. However, NK cells identify tumour cells via 
the integration of signals through activating and inhibitory receptors. In 
response to activating receptor ligation, NK cells produce IFN-γ, TNF, GM-
CSF and TNFSF14 that enhance anti-tumour activity (Holmes et al., 2014). 
GM-CSF promotes the maturation of local monocytes into DCs, whereas IFN-
γ, TNF and TNFSF14 enhance antigen presentation and favour the 
maturation and activation of DCs. Subsequently, activated DCs express IL-15 
which enhances NK cell survival and activation. Thus, through their ability to 
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identify “altered self” and produce DC activating cytokines, NK cells provide a 
surveillance function against self-cells that lack PAMPs (Holmes et al., 2014).  
 
1.5.4 NK-DC crosstalk 
NK-DC interactions are important mediators of the immune response, 
reciprocally activating one another at sites of inflammation and in the LN 
(Thomas and Yang, 2016). As previously mentioned, DCs activate NK cells 
which subsequently promote the maturation and activation of DCs (Ferlazzo 
and Morandi, 2014). This activation is dependent on the secretion of soluble 
inflammatory mediators, such as DC-derived IL-12 and NK cell-derived IFN-
γ, and also cell-to-cell contact (Gerosa et al., 2002, Piccioli et al., 2002). In 
fact, NK-DC conjugates enable the polarised secretion of IL-12 across a 
synapse towards NK cells to induce IFN-γ expression (Borg et al., 2004). 
Additionally, NK-DC conjugation enables NK cells to recognise and kill 
immature DCs (through low MHC I expression), thereby selecting mature DCs 
that will subsequently provide better T cell activation (Morandi et al., 2012). 
1.5.5. Interferon gamma regulation 
NK cell-derived IFN-γ is finely tuned and dependent on the stimulus. Studies 
have shown that different combinations of cytokines induce IFN-γ production 
to different extents, for example, IL-12 and IL-18 are both potent inducers of 
IFN-γ and can act synergistically with other cytokines to enhance IFN-γ 
secretion (Nielsen et al., 2016, Freeman, 2015). IL-18 has also been shown 
to synergise with type 1 IFNs during viral infections ((Matikainen et al., 2001), 
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whilst IL-21 and IL-18 have been shown to enhance IL-15 mediated 
expression of IFN-γ (Strengell et al., 2003).  
 
1.5.6 Cytokine secretion 
Secretion of the pro-inflammatory cytokines IFN-γ and TNF is distinct from 
perforin secretion. Unlike the polarised release of perforin across a synapse 
towards a target cell, IFN-γ and TNF are secreted from the entire cell surface 
in a non-polarised manner via the conventional secretory pathway (Reefman 
et al., 2010). 
 
1.6 IL-15 regulated NK cell activity 
In addition to receptor ligation, NK cell activity is regulated by cytokines. 
Pathogens induce a plethora of immunomodulatory cytokine secretion which 
then modulate immune cell functions such as proliferation and activation. In 
particular, IL-15 is central to NK cell development and function; stimulating the 
differentiation, survival and activation of NK cells (Huntington, 2014).  
 
1.6.1 Development 
Studies in mouse models highlight the critical role of IL-15 in NK cell 
development. Bone marrow stromal cell-derived IL-15 is essential to promote 
the differentiation of CD34
+ 
progenitor cells into NK cells (Mrózek E, 1996), 
and mice that are deficient in IL-15 (IL-15-/-) or the IL-15R (IL-15R-/-) have 
profoundly reduced NK cell numbers. In IL-15-/- mice, the addition of 
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exogenous IL-15 can reverse NK cell deficiency, underlining the important role 
of IL-15 in NK cell expansion (Lodolce et al., 1998, Kennedy et al., 2000). 
Moreover, IL-15R-/- mice have  significantly smaller lymph nodes than wild-
type (WT) mice, caused by reduced homing to the lymph node, and reduced 
proliferation of cells in the lymph nodes (Lodolce et al., 1998).  
 
1.6.2 Survival  
The survival of NK cells is also mediated by IL-15. IL-15 supports the survival 
of NK cells by enhancing the expression of anti-apoptotic proteins (e.g. Bcl-2, 
Mcl-1) (Cooper et al., 2002, Ranson et al., 2003) and inhibiting the expression 
of pro-apoptotic proteins (e.g. Bim, Noxa, Puma) (Huntington et al., 2007, 
Inoue et al., 2010). This was first demonstrated by Cooper et al. using IL-15 
knockout mouse models. NK cells that had been adoptively transferred into 
IL-15-/- failed to survive beyond 5 days, whereas NK cells transferred into IL-
15+/- or WT mice could still be detected at this time-point. The anti-apoptotic 
protein Bcl-2 was identified as a key regulator of this survival, accordingly, 
adoptively transferred cells from mice overexpressing Bcl-2 could survive in 
lL-15-/- mice (Cooper et al., 2002). In addition to Bcl-2, IL-15 induced 
expression of the anti-apoptotic protein Mcl-1 has also been identified as a 
key regulator of NK cell survival (Huntington et al., 2007, Sathe et al., 2014). 
Mcl-1 has also been implicated in the development and differentiation of NK 
cells. Specific deletion of Mcl-1 in murine NK cells resulted in the complete 
loss of mature NK cells with only a minor population of immature NK cell 
remaining (Sathe et al., 2014).  
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Aside from anti-apoptotic proteins, IL-15 regulation of pro-apoptotic 
proteins also contributes to NK cell survival. IL-15 downregulates expression 
of the pro-apoptotic protein Bim through multiple different mechanisms. 
Firstly, IL-15 stimulation of the Erk1/2 pathway targets Bim for proteosomal 
degradation, secondly; IL-15 suppresses the transcription of Bim in a 




IL-15 is the prototypical activator of NK cells and, as such, mediates multiple 
mechanisms that contribute to the robust activation of NK cells. Key activation 
mechanisms such as proliferation, cytotoxicity and cytokine production are all 
induced in response to IL-15 stimulation (Carson et al., 1994, Dunne et al., 
2001, Holmes et al., 2014, Anton et al., 2015, Wagner et al., 2017). 
Furthermore, the expression of activating receptors such as NKG2D, DNAM1, 
NKp46 and NKp30 are all upregulated in response to IL-15 (Wilson et al., 
2011, de Rham et al., 2007). As previously mentioned, activated DCs are a 
key source of IL-15 and therefore potent activators of NK cell effector function 
(Nguyen et al., 2002, Baranek et al., 2012).  
IL-15 signals through a member of the common γ-chain family of cytokine 
receptors. Receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 all utilise the 
common γ-chain (CD132) as the signalling chain of their receptor complex. 
The IL-15 receptor is a heterotrimeric receptor comprised of the ligand binding 
domain (IL-15Rα), the IL-2Rβ (CD122) and CD132, the latter two components 
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of which it shares with the IL-2 receptor (Mishra et al., 2014, Lodolce et al., 
2002). IL-15 initiates signalling through trans-presentation of soluble or 
membrane bound IL-15/IL-15Rα complexes to the CD122/CD132 complex 
(Lucas et al., 2007, Stonier and Schluns, 2010, Huntington et al., 2009, Zanoni 
et al., 2013). Cis-presentation of IL-15 has also been identified in NK cells. 
Unlike trans-presentation that requires cell-to-cell contact, cis-presentation 
requires the NK cell derived IL-15/IL-15Rα complex to be displayed on the cell 
surface where it can interact with the CD122/CD132 complex (Zanoni et al., 
2013, Stonier and Schluns, 2010). While IL-15 can bind the CD122/CD132 in 
the absence of IL-15Rα, it has much higher affinity for IL-15Rα (Carson et al., 
1994, Guo et al., 2017). 
Like many cytokines, IL-15 utilises the Janus Kinase (JAK)- signal 
transducer and activator of transcription (STAT) signalling pathways to 
transduce signalling, specifically through the phosphorylation and activation 
of JAK1/3, STAT5 and STAT3 (Johnston et al., 1995, Lodolce et al., 2002). 
Additionally, IL-15 has also been shown to utilise other signalling pathways 
downstream of IL-15 receptor binding, including the PI3K and mitogen-
activated protein kinase (MAPK) pathways (Wagner et al., 2017). Through 
these pathway, IL-15 regulates gene expression of anti-apoptotic and pro-
inflammatory mediators that enhance the activation and survival of NK cells 
(Mishra et al., 2014).  
Recently, IL-15 has been shown to regulate the immunometabolism of 
NK cells via the mammalian target of rapamycin (mTOR) pathway. Several 
studies have suggested that IL-15 stimulation induces a metabolic switch that 
increases the rate of glycolysis and oxidative phosphorylation (OXPHOS) that 
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is regulated by activation of the mTOR pathway (Nandagopal et al., 2014, 
Marçais et al., 2014). In particular, mTOR activation and the subsequent 
metabolic changes have been shown to enhance IFΝ-γ production, 
proliferation and anti-tumor activity (Donnelly et al., 2014, Nandagopal et al., 
2014, Marçais et al., 2014). 
 
1.7 TGF-β regulated NK cell activity 
Transforming growth factor-beta (TGF-β) can impact the activity of most cell 
types; hence, it plays a role in several physiological and immunological 
processes (David and Massagué, 2018). In immunological processes, TGF-β 
is a prominent immunosuppressive cytokine that regulates inflammation via 
multiple mechanisms.  For example, TGF-β mediated the differentiation of T 
cell subsets by supressing the differentiation of T helper cells and promoting 
the differentiation of T regulatory cells (Tregs) (Sanjabi et al., 2017, Yoshimura 
et al., 2010).  
The canonical signalling pathway for TGF-β requires the 
phosphorylation and activation of downstream Smad proteins. Briefly, TGF-β 
binds to a heterotrimeric receptor comprised of one TGF-β receptor 1 
(TGFBR1) chain and two TGFBR2 chains. Ligation of the receptor induces 
the phosphorylation of receptor-regulated Smads (R-Smads) 2 and 3, 
followed by the binding of cytoplasmic Smad 4 to form a transcriptional 
complex which translocates to the nucleus and binds hundreds of different loci 
throughout the genome (Heldin and Moustakas, 2016, Batlle and Massagué, 
2019). This transcriptional complex binds DNA in combination with other co-
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transcription factors (co-activators or co-repressors), the availability of which 
helps determine context specific responses (Mullen et al., 2011). Inhibitory 
Smads, Smad 6 and 7, are also regulated by TGF-β and provide a negative 
feedback loop by regulating TGFBR degradation (Batlle and Massagué, 
2019).  Additionally, MAPK and PI3K signalling has also been identified 
downstream of TGF-β signalling (Lee et al., 2007, Heldin and Moustakas, 
2016); however, these Smad-independent pathways are less well-defined.  
The role of TGF-β in tumour progression is not straightforward, with studies 
detailing tumour suppressive and tumour promoting actions of TGF-β (Honjo 
et al., 2007, Liang et al., 2016). Generally, TGF-β supresses tumour 
progression through several mechanisms, including triggering apoptosis in 
cells harbouring oncogenic mutation and inhibiting the proliferation of cells 
through the upregulation of cell cycle inhibitors (Batlle and Massagué, 2019). 
However, TGF-β is a potent inhibitor of T cell and NK cell effector functions 
which can indirectly promote tumour progression (Sanjabi et al., 2017, 
Yoshimura et al., 2010). Tumour cells themselves frequently become 
refractory to the action of TGF-β, e.g. via mutations in the receptor or in 
signalling components. Thus, in a TGF-β rich tumour microenvironment, the 
tumour maybe unaffected but immunity will be impaired (Seoane and Gomis, 
2017).  
In NK cells, TGF-β signalling has been shown to inhibit several 
activation mechanisms, including cytokine induced NK cell proliferation, 
cytokine secretion and cytotoxicity (Bellone et al., 1995, Viel et al., 2016, Yu 
et al., 2006, Zaiatz-Bittencourt et al., 2018). Furthermore, TGF-β inhibits IL-
15 mediated upregulation of activating receptors such as NKG2D, DNAM1, 
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NKp30 and NKp46  (Wilson et al., 2011, Crane et al., 2009). However, the 
molecular mechanisms that mediate TGF-β inhibition of NK cell activation are 
largely unknown. While some studies highlight the role of canonical TGF-β in 
NK cell inhibition (Trotta et al., 2008, Yu et al., 2006), other mechanisms have 
also been suggested. In particular, one study recently identified mTOR as a 
key target of TGF-β inhibition.  In this study, TGF-β and the mTOR inhibitor, 
rapamycin, were shown to have comparable effects. In IL-15 stimulated NK 
cells, TGF-β inhibited the proliferation, metabolism and cytotoxicity of NK cells 
in an mTOR dependent manner. In response to TGF-β, NK cells had reduced 
expression of cytolytic proteins coupled with reduced ability to kill target cells. 
Moreover, Tgfbr2-/- NK cells had increased phosphorylation of S6 
(downstream of mTOR), but no difference in STAT5 phosphorylation when 
compared to WT cells, suggesting that mTOR rather STAT5 is a key target of 
TGF-β (Viel et al., 2016).  
In contrast to this, a recent study reported that canonical TGF-β 
signalling mediates inhibition of NK cell function independently of mTOR 
inhibition (Zaiatz-Bittencourt et al., 2018). As described, the signalling 
pathways utilised by TGF-β have not been fully elucidated; therefore, further 
investigation into TGF-β-NK cell interactions are needed.  
 
1.8 Interleukin 10 
Primarily described as an immunosuppressive cytokine, interleukin-10 (IL-10) 
is a key regulator of immunity. Originally named ‘cytokine synthesis inhibitory 
factor’, IL-10 was first identified as a factor secreted from Th2 clones that 
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could inhibit the production of cytokines from Th1 clones (Fiorentino et al., 
1989). In many cell types, IL-10 is a potent immunosuppressor and works to 
limit the immune response and prevent autoimmune or inflammatory 
pathologies (Couper et al., 2008) (see section 1.8.4). However, increasingly, 
the immunosuppressive designation of IL-10 is being challenged. A growing 
number of studies detail immunostimulatory activities of IL-10 in a range of 
different cell types, leading to the acknowledgement that IL-10 is in fact a 
pleiotropic cytokine with multiple functions (Mocellin et al., 2003) (see section 
1.8.5).  
 
1.8.1 Sources of IL-10 
Although T cells are still considered to be a main source of IL-10, it is now 
widely accepted that IL-10 is produced from almost all leukocytes. IL-10 
production is regulated in a cell-type dependent manner, and cell-specific 
secretion of IL-10 mediates different environments (Saraiva and O'Garra, 
2010). For instance, IL-10 plays a pivotal role in gut homeostasis (Zhou and 
Sonnenberg, 2018) and a specific role for T cell-derived IL-10 has been 
highlighted. Conditional deletion of Il-10 in murine CD4+ T cells resulted in 
intestinal inflammation leading to the development of inflammatory bowel 
disease (IBD) (Roers et al., 2004). In contrast, myeloid-derived IL-10, but not 
T cell-derived IL-10 was shown to be important in the context of 
lipopolysaccharide (LPS) infection. In this model, selective inactivation of Il-10 
in monocytes and neutrophils increased the sensitivity to LPS infection and 
enhanced leukocyte infiltration, whereas mice with Il-10 deficient T cells had 
a similar response to WT mice (Siewe et al., 2006). 
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1.8.2 IL-10 in Disease 
The central role of IL-10 in immunity dictates that aberrant expression or 
activity of IL-10 will impact upon many immunological processes. As such, IL-
10 is known to contribute to the pathogenesis of several autoimmune and 
autoinflammatory diseases such IBD, psoriasis and rheumatoid arthritis 
(Ouyang, 2011, Trifunović et al., 2015). The non-redundant, anti-inflammatory 
role of IL-10 in IBD is emphasised in knockout mouse models. Animals 
deficient in IL-10 (Il-10-/-) have exaggerated responses to gut microbiota and 
uncontrolled intestinal inflammation (Kühn et al., 1993). In humans, loss of 
function mutations in IL-10 or IL-10R are associated with very early onset IBD, 
characterised by severe IBD symptoms, and infantile IBD (Kotlarz et al., 2012, 
Zhu et al., 2017, Lee et al., 2014). Dysregulated expression of IL-10 is also a 
factor in the pathology of psoriasis. Patients with psoriasis have reduced 
levels of IL-10 (Al-Robaee et al., 2008, Asadullah et al., 1998), often in 
combination with elevated levels of pro-inflammatory cytokines such as IL-8, 
IL-12 and IL-19 (Hofmann et al., 2012). The risk of psoriasis can also correlate 
with genetic alteration of IL-10, specifically polymorphisms in the IL-10 
promoter region (Karam et al., 2014). In contrast to diseases characterised by 
IL-10 deficiency, patients with rheumatoid arthritis have elevated levels of 
serum and synovial fluid IL-10. In these patients, the pleiotropic role of IL-10 
is evident, with IL-10 supressing the expression of pro-inflammatory cytokines 
whilst promoting the secretion of autoantibodies. Accordingly, the 
overexpression of IL-10 is associated with expression of rheumatoid factor 
(RF) and anti-cyclic citrullinated peptide (CCP) autoantibodies  (Hernández-
Bello et al., 2017).  
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1.8.3 IL-10 Signalling 
IL-10 exerts its biological effects through extracellular binding of cell surface 
receptors IL-10R1(α) and IL-10R2(β). Upon receptor engagement, the IL-10R 
transduces signals through multiple pathways, of which the JAK-STAT 
pathway is the most well-characterised (Verma et al., 2016).  The IL-10 
receptors form a tetrameric complex consisting of two IL-10R1 and two IL-
10R2 chains (Figure 3) (Carey et al., 2012). Each receptor has distinct 
functions based on their affinity for IL-10. IL-10R1 has greater affinity and is 
the specific ligand binding chain, whereas IL-10R2 has lower affinity and acts 
as an accessory chain (Walter, 2014). IL-10R2 does not physically bind to IL-
10 but instead associates with the IL-10/IL-10R1 complex and activates the 
signalling cascade. IL-10R2 does not affect the affinity of IL-10R1/IL-10 
binding, but expression of both receptors is essential to activate the JAK/STAT 
signal transduction pathway (Ding et al., 2001). Upon receptor/ligand binding, 
JAK1 (Janus Kinase 1) and Tyk2 (Tyrosine kinase 2) phosphorylate 
themselves and trans-phosphorylate tyrosine resides on IL-10R1 which acts 
as a docking site to recruit STAT3. Following this, STAT3 is phosphorylated, 
resulting in the homo/hetero-dimerisation of STAT3 proteins, translocation to 
the nucleus and subsequent regulation of gene expression (Glocker et al., 
2011) (Figure 3). As mentioned, multiple pathways have been identified in IL-
10 signalling (e.g. PI3K/Akt signalling regulates the expression of a subset of 
IL-10 inducible genes in macrophages (Antoniv and Ivashkiv, 2011), detailing 
a complex network of pathways that are yet to be fully elucidated (Verma et 
al., 2016).  
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1.8.4 Anti-inflammatory activity of IL-10 
The anti-inflammatory effect of IL-10 have been extensively studied and a 
number of IL-10 mediated effects have been identified (Akdis and Blaser, 
2001, Hutchins et al., 2013, Couper et al., 2008). Perhaps the most well-
known function of IL-10 is the suppression of monocyte/macrophage activity. 
For example, IL-10 suppresses the production of pro-inflammatory cytokines 
from activated macrophages (Fiorentino et al., 1991, Oswald et al., 1992), and 
inhibits antigen presentation in monocytes/macrophages via the 
downregulation of MHC II expression. Additionally, IL-10 induces the 
expression of Membrane-associated RING-CH protein I (MARCH-I) that 
ubiquitinates MHC II leading to its lysosomal degradation, a mode of action 
that indirectly inhibits T cell activation (Mittal and Roche, 2015). Furthermore, 
IL-10 has been shown to negatively regulate NF-κB activity. IL-10 induced 
STAT3 positively regulates the transcription of several anti-inflammatory 
response (AIR) factors, such as BCL3 and ETV3, which suppress NK-κB 
mediated gene expression (Hutchins et al., 2013). IL-10 also induces the 
expression of microRNAs that negatively regulative APC activity by 
supressing TLR signalling (Curtale et al., 2013).  
Whilst IL-10 indirectly inhibits NK cell and T cell activity through APC-
dependent mechanisms (Couper et al., 2008), direct inhibition of NK cell and 
T cell activity has also been reported. In a murine model of retroviral infection, 
neutralisation of Treg derived IL-10 was shown to enhance NK cell 
proliferation and activity independent of effects on APC activation, suggesting 
IL-10 directly inhibits NK cells in this model (Littwitz-Salomon et al., 2018).  
 - 44 - 
Conversely, in vitro analysis of isolated murine NK cells suggests that IL-10 
has limited direct effect on NK cell proliferation and cytotoxicity (Brady et al., 
2010). In a murine model of lymphocytic choriomeningitis virus (LCMV) 
infection, IL-10 was shown to inhibit the expansion of CD4
+
 but not CD8
+
 
memory T cells (Brooks et al., 2010); however, IL-10 was shown to directly 
inhibit the expansion of CD8
+
 memory T cells in a murine model of Listeria 
monocytogenes infection (Biswas et al., 2007). Additionally, IL-10 has also 
been shown to inhibit CD8
+
 T cell responses by decreasing antigen specificity, 
thereby increasing the threshold for activation, through enhancing branching 
of cell surface glycoproteins (Smith et al., 2018b). 
Further evidence to support the anti-inflammatory role of IL-10 can be 
demonstrated by viral infections that manipulate IL-10 to benefit pathogen 
survival. Viruses can suppress immune activation by upregulating the 
expression of cellular IL-10. Furthermore, HCMV (Human cytomegalovirus) 
and EBV encode orthologues of IL-10 (vIL-10) which have been shown to 
exhibit comparable biological functions to human IL-10 (Ouyang et al., 2014), 
providing a virus-encoded strategy to evade immunity and favour viral 
replication. 
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Figure 3: IL-10-STAT3 signalling pathway 
IL-10 mediates the transcription of genes through activation of the STAT3 pathway. 
IL-10 binds to the IL-10R, causing the downstream phosphorylation and 
modernisation of STAT3 molecules. Subsequently, these dimers translocate to the 
nucleus where they regulate the expression of STAT3 responsive genes. Figure 
adapted from (Glocker et al., 2011). 
IL: interleukin; JAK: Janus kinase; P: phosphate; R1: receptor 1; R2: receptor 2; 
STAT: signal transducer and activator of transcription; TYK2: tyrosine kinase 2.  
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1.8.5 Pro-Inflammatory activity of IL-10  
Undoubtedly, IL-10 is an immunosuppressive cytokine in a multitude of cell 
types and environments. However, there is an increasing number of studies 
that report immunostimulatory functions of IL-10. Immunostimulatory activities 
have been demonstrated in multiple cell types, including B cells, mast cells, T 
cells and NK cells.  
In B cells, stimulation of TLR9, CD40 and IL-4R induces the expression 
of IL-10. This autocrine IL-10 then promotes the differentiation of B cells into 
IgM and IgG secreting plasmablasts, therefore promoting humoral immune 
responses (Heine et al., 2014). As with many cytokines, the effects of IL-10 
on B cell activation is thought to be context dependent, i.e pre or post-
activation (Itoh and Hirohata, 1995). 
Similarly, activatory effects have been identified in mast cells (Qayum 
et al., 2016). In a mouse model of food allergy, IL-10 played an essential role 
in the proliferation and activation of mast cells, including the upregulation of 
mast cell-derived cytokines and the expression of FcεRI that mediated IgE 
responses (Polukort et al., 2016). 
IL-10 mediated activation has also been noted in the context of the 
tumour microenvironment. In a mouse model of pre-established tumours, 
intra-tumoural IL-10 treatment resulted in infiltration of CTLs, increased intra-
tumoural expression of MHC molecules and elevated levels of IFN-γ. 
Moreover, infiltrating CTLs displayed a 3-4-fold increase in IFN-γ and 
granzyme B secretion and greater expression of IL-10R1 when compared to 
peripheral T cells (Mumm et al., 2011). IL-10 has also been shown to induce 
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the activation and proliferation of tumour resident CTLs, leading to tumour 
rejection (Emmerich et al., 2012). 
Many studies report that IL-10 activates NK cells, but the molecular 
mechanisms that regulate this are largely unknown. Several studies have 
investigated the impact of IL-10 on cytokine production, cytotoxicity and 
proliferation of NK cells. In the presence of IL-2, IL-10 enhanced the 
production of IFN-γ, TNF and GM-CSF (Carson et al., 1995). Similarly, IL-10 
could enhance IFN-γ production in combination with IL-18, but not IL-12 (Cai 
et al., 1999). These studies also report that IL-10 alone was not sufficient to 
induce the production of these cytokines. IL-10 also enhanced NK cell 
cytotoxicity, alone or in combination with other activating cytokines. For 
instance, combinations of IL-2 and IL-10 or IL-15 and IL-10 enhance 
cytotoxicity resulting in increased lysis of target cells; an effect that could be 
inhibited by IL-10 neutralisation  (Carson et al., 1995, Cai et al., 1999, Park et 
al., 2011). Additionally, IL-10 alone did not induce NK cell proliferation but 
could potentiate the proliferative effects of other cytokines (Cai et al., 1999). 
One particular study reported contradictory results from in vitro and in vivo 
models. In vivo, post-LPS administration of IL-10 increased serum levels of 
granzyme B, IFN-γ and IFN-γ-dependent chemokines CXCL10 and CXCL9. 
However, in in vitro models, these stimulatory effects were not observed and 
IL-10 inhibited the production of IFN-γ (Lauw et al., 2000). Data in these 
studies are generated from several different NK cell sources, including NK 
cells within whole blood, isolated human NK cells, NK cells differentiated from 
CD34
+
 HSCs, murine NK cells and the NK-like cell line NK-92, which may 
impact the observations detailed here (Cai et al., 1999, Carson et al., 1995, 
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Park et al., 2011, Lauw et al., 2000). With increasing amounts of evidence 
supporting a pro-inflammatory role, particularly in the context of NK cells, it is 
important to investigate these mechanisms further.  
 
1.9 Aim  
The overall aim of this thesis is to improve our understanding of NK cell 
activity, and how this is controlled by cytokines. The goal of this study is to 
explore the immunomodulatory effects of IL-10 on NK cells. As described, 
existing literature regarding the function of IL-10 is somewhat ambiguous; with 
data generated from multiple sources of NK cell-like lines, animal models and 
primary cells. Although generally described as immunosuppressive, a number 
of studies have highlighted the immunostimulatory function of IL-10 in multiple 
cell types, including NK cells. In light of this, I aim to resolve the contradictory 
findings of IL-10 function using human primary NK cells.  
To do this, an in vitro system was used to culture human primary NK cells 
in the presence of IL-10 and subsequent downstream assays were performed 
to assess IL-10-induced activity. In particular, the signalling pathways and 
resulting activatory/inhibitory impact of IL-10 stimulation was investigated. 
Additionally, IL-10-induced NK cell responses were compared to IL-15- and 
TGF-β-induced NK cell responses, as these are known to potently activate 
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Chapter 2 
Materials and methods 
2.1 Cell Culture 
2.1.1 Peripheral Blood Mononuclear Cell Isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donor 
apheresis cones (obtained from NHS blood and transplant, Leeds) by density 
gradient centrifugation using Lymphoprep™ (Axis-Shield). Blood was diluted 
1:6 or 1:11 with Phosphate Buffered Saline (PBS), 30 mL was then carefully 
layered onto 15 mL of room temperature (RT) Lymphoprep in a 50 mL 
centrifuge tube and centrifuged at 800 x g for 20 minutes at RT with no brake 
(all centrifugations were carried out using an Eppendorf 5810). The PBMC 
interface (Figure 4) was then transferred to a new 50 mL centrifuge tube by 
pastette, resuspended in PBS and centrifuged at 220 x g for 15 minutes (brake 
on). The supernatant was aspirated and the PBMCs were resuspended in 
PBS, cell number was determined by counting with a haemocytometer before 
centrifuging at 300 x g for 5 minutes. The supernatant was discarded and the 
PBMCs were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium (Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum (FBS) 
(Sigma-Aldrich) at a density of 2 x 10
6
/mL; cells were maintained at 37°C in a 
humidified atmosphere containing 5% carbon dioxide (CO2) using a CO2 
incubator (Sanyo).
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2.1.2 Natural Killer cell isolation 
NK cells were purified from isolated PBMCs (described in section 2.1.1) using 
a negative selection method which provides a highly pure population of 
untouched NK cells (routinely >95% when tested) by depletion of magnetically 
labelled non-NK cells (Figure 5). Human NK Cell Isolation Kit and LS columns 
(Miltenyi Biotec) were used according to manufacturer’s instructions. 1 x 10
7
 
PBMCs are used per column to obtain an approximate yield of 1 x 10
6
 NK 
cells. NK cells were isolated directly after PBMC isolation or after overnight 
incubation. PBMCs were centrifuged at 300 x g for 10 minutes (4˚C) and 
resuspended in 440 µL of ice-cold MACS buffer (10% bovine serum albumin 
(BSA) and 0.5M EDTA in PBS) and 110 µL of a cocktail of biotin-conjugated 
antibodies against non-NK cell specific antigens. After incubation at 4°C for 5 
minutes, 330 µL of ice-cold MACS buffer containing 220 µL of anti-biotin 
magnetic beads was added and incubated at 4°C for a further 10 minutes. LS 
columns were mounted onto a MACS magnetic stand and equilibrated with 3 
mL MACS buffer, the cell suspension was passed through the columns and 
flushed with a further 9 mL of ice-cold MACS buffer. Labelled non-NK cells 
were retained in the LS column and the eluted untouched NK cells collected 
in a 15-mL centrifuge tube. NK cells were pelleted (300 x g for 10 minutes) 
and cultured at 1 x 10
6
/mL in Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma-Aldrich) and 10% human AB serum (Gemini Bio-Products) at 37°C, 
5% CO2. 
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Figure 4: Lymphoprep density gradient centrifugation 
Blood /PBS is layered onto Lymphoprep, during centrifugation high-density 
erythrocytes positon at the bottom of the tubes whilst the PBMC layer is positioned 
at the interface of the Lymphoprep and the plasma layer. 
PBMC: peripheral blood mononuclear cell 
 
 
Figure 5: Examples of NK cell isolation from PBMCs 
NK cells were isolated from PBMCs as described in section 2.1.2 and incubated for 
48 hours (as untreated controls). Cells were then stained with anti-CD56 and anti-
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2.1.3 Cell Stimulation  
PBMCs or NK cells were cultured as described in section 2.1.1 and 2.1.2, 
respectively. Cells were transferred to appropriately sized cell-culture plates 
and stimulated with purified cytokines and reagents at the concentrations 





IL-10 50 ng/mL Miltenyi Biotec 
IL-15 20 ng/mL Miltenyi Biotec 
IL-12 1 ng/mL R&D systems 
IL-18 5 ng/mL R&D systems 
IL-21 50 ng/mL Miltenyi Biotec 
IL-1β 10 ng/mL R& D systems 
LPS (E. Coli k12) 100 ng/mL Invivogen Ultrapure 
TGF-β 5 ng/mL Miltenyi Biotec 
c188-9 1, 5, 10 μM Merck Millipore 
Palbociclib (PD-0332991) 1 µM Sigma-Aldrich 
 
Table 2: Cytokines/reagents used to stimulate NK cells 
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2.1.4 Cell Lines 
K562 
The K562 cell line is derived from a patient with chronic myelogenous 
leukaemia (CML) (Lozzio, 1975). It is a non-adherent cell line that is a well 
validated in-vitro target for NK cells (Zarcone et al., 1987). Cells were cultured 





 cells/mL at 37°C, 5% CO2.  
SKOV3 
The SKOV3 cell line is an adherent cell line derived from a patient with ovarian 
adenocarcinoma. Cells were kindly provided by Dr Victoria Jennings, 
University of Leeds, and cultured in DMEM (Sigma-Aldrich) and 10% FBS at 
37°C, 5% CO2. Before using cells in assays, culture medium was removed 
and cells were gently washed by adding PBS to the flask. The PBS was then 
discarded and cells were harvested by adding 2 mL of 1X trypsin (Sigma-
Aldrich) and incubating at 37˚C for approximately 5 minutes, cell detachment 
was confirmed by microscope observation. Cells were then resuspended in 
culture medium and centrifuged at 300 x g for 5 minutes. Cells were 
resuspended in culture medium at the appropriate density and transferred into 
new cell-culture plates to be used in subsequent assays. 
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2.2 Flow Cytometry 
Flow Cytometry was performed using either an LSRII flow cytometer (BD 
Biosciences) and data was analysed using FACSDiva software (BD 
biosciences), or using the Cytoflex (Beckman Coulter) with analysis software 
CytExpert 2.1. Where appropriate, isotype controls were included to assess 
background staining. Gates for positive staining were set at 2% based on the 
isotype staining. Single fluorophore controls were used for compensation 
where needed. Antibodies, reagents and isotypes used for flow cytometry can 
be found in tables 3-5. 
  
2.2.1 Surface Staining  
Cells were harvested into 5 mL round bottom polystyrene tubes (FACS tubes) 
and washed twice in FACS buffer (0.5% BSA and 0.09% sodium azide in PBS) 
(300 x g for 5 minutes). Cells were then resuspended at approximately 1 x 106 
cells/100 µL in FACS buffer containing relevant antibodies and incubated for 
30 minutes at 4°C protected from light. Cells were then washed twice (300 x 
g for 5 minutes) and resuspended in 300 µL FACS buffer before flow 
cytometric analysis.  
 
2.2.2 Intracellular Staining  
Cells were transferred into 15 mL centrifuge tubes and fixed using Cytofix 
fixation buffer (BD Biosciences). Pre-warmed (37°C) Cytofix was added in 
equal volume to the cell suspension and incubated at 37°C for 10 minutes in 
a water bath. Cells were centrifuged at 600 x g for 6 minutes, the supernatant 
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was discarded, and the pellet was resuspended in 1 mL of cold Perm Buffer 
III (BD Biosciences) and incubated on ice for 30 minutes. Cells were then 
transferred to FACS tubes and washed three times in stain buffer (2% FCS 
and 0.09% sodium azide in PBS) (600 x g for 6 minutes) before being 
resuspended in stain buffer (approximately 1 x 10
6
/100 µL) containing relevant 
antibodies or isotype controls for 1 hour at RT, protected from light. Cells were 
then washed twice (600 x g for 6 minutes) and resuspended in 300 µL stain 
buffer before flow cytometric analysis. 
 
2.2.3 Intracellular cytokine staining 
GolgiStop (BD Biosciences) and GolgiPlug (BD Biosciences) were added to 
NK cells at 1:1500 and 1:1000, respectively and incubated at 37˚C for 5 hours. 
Cells were then transferred to FACS tubes, and washed in FACS buffer at 300 
x g for 5 minutes. Cells were resuspended in 100 µL FACS buffer and stained 
with anti-CD3 and anti-CD56 antibodies for 30 minutes at 4˚C, protected from 
light. Cells were then washed twice in FACS buffer at 300 x g for 5 minutes 
before resuspending in 100 µL FACS buffer and 100 µL intracellular fix buffer 
(eBioscience) and incubating at RT for 30 minutes, protected from light. Cells 
were then washed twice in intracellular permeabilisation buffer (eBioscience) 
(diluted 1:10 with PBS fresh before use) (300 x g for 5 minutes) and 
resuspended in 50 µL intracellular permeabilisation buffer and 10 µL anti-IFN-
γ antibody and incubated at RT for 30 minutes, protected from light. Cells were 
washed again in intracellular permeabilisation buffer at 600 x g for 5 minutes 
and resuspended in 300 µL FACS buffer before being analysed by flow 
cytometry.   
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2.3 Cytotoxicity Assays 
NK cells were stimulated with cytokines (previously described) for 48 hours 
prior to being used in these assays. K562 target cells (10
6
/mL) were labelled 
with a fluorescent dye before being co-cultured with NK cells. K562 cells were 




gh)coumarin) dye (CTV) (Invitrogen) or 0.4 µM CellTrackerTM green CMFDA 
(5-chloromethylfluorescein diacetate) dye (Invitrogen), and incubated at 37˚C 
for 30-45 minutes. Labelled target cells were washed twice in media and 
resuspended in fresh media at 10
6
/mL, then transferred into 96-well round 
bottomed cell-culture plates. NK cells (effectors) were then added at effector 
to target (E: T) ratios of 1:1, 2:1, and 5:1, and incubated for 4 hours at 37°C, 
5% CO2. After incubation, the cells were pelleted (300 x g for 5 minutes), 
washed in PBS (300 x g for 5 minutes) and resuspended in 50 µL Zombie 
NIR™ (Biolegend) (1:1000 with PBS) and incubated on ice, protected from 
light for 20 minutes. Finally, the cells were pelleted (300 x g for 5 minutes), 
washed in PBS (300 x g for 5 minutes) and resuspended in 150 µL FACS 
buffer before being analysed on a Cytoflex cytometer (Beckman Coulter). 
Control wells included target cells alone and NK cells alone stained with 
Zombie NIR™ to measure spontaneous cell death. 
 
2.4 Degranulation assays 
NK cells and targets were prepared as in section 2.1.2 and effectors and 
targets were co-cultured at 1:1 in 96-well round bottomed cell-culture plates. 
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After 1 hour incubation at 37˚C, an anti-CD107a (1:40) antibody and GolgiStop 
(BD Biosciences) (1:1000) were added. The plate was then incubated at 37˚C 
for a further 4 hours. Cells were then pelleted and washed in PBS (300 x g for 
5 minutes), before being resuspended in 150 µl FACS buffer and analysed on 
a the Cytoflex cytometer (Beckman Coulter). Control wells included target 
cells alone and NK cells alone stained with anti-CD107a to measure 
spontaneous degranulation events.  
 
2.5 Glucose fluxing analysis 
NK cells were stimulated for 48 hours prior to being used in this assay. NK 
cells were washed out of NK cell media (300 x g 5 minutes), resuspended in 
pre-warmed glucose free RPMI (Sigma-Aldrich) supplemented with 10% FCS 
and incubated at 37˚C. After 15 minutes, 50 µM 2-NBDG (2-[N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglucose) (Invitrogen) was added and 
the cells were then further incubated at 37˚C for 60 mins. Cells were then 
transferred to centrifuge tubes (on ice) and washed twice in ice cold PBS (300 
x g 5 minutes). The cells were then resuspended in 500 µL PBS, transferred 
to FACS tubes and analysed by flow cytometry.  
 
2.6 Cell Cycle Analysis (Propidium Iodide) 
Isolated NK cells were treated with cytokines and incubated at 37°C for 96 
hours. NK cells were then harvested into FACS tubes and washed twice in 
PBS (300 x g for 5 minutes). After washing, cells were fixed in ice-cold 70% 
ethanol by adding the ethanol dropwise to the cells whilst being gently 
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vortexed (1 x 10
6
 cells/mL). Cells were then incubated on ice for 30 minutes 
and stored at -20°C overnight. Cells were then washed in stain buffer (600 x 
g for 5 minutes) three times before adding 50 µl of 100µg/mL RNAse A 
(Qiagen) directly to the cell pellet. Cells were then resuspended in 300 μL 
stain buffer containing 20 μL/10
6
 cells propidium iodide (PI) (Life 
technologies). Cells were incubated for 30 minutes at RT, protected from light, 
then analysed with the LSRII flow cytometer.  
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Target Fluorophore Manufacturer Clone Volume 
CD3 
BV421 BD horizon SK7 2/100 



















FITC Biolegend FN50 5/100 












































Table 3: Antibodies used for flow cytometry 
APC (Allocophycyanin), FITC (Fluorescein isothiocyanate), PE 
(phycoerythrin) and BV-421(brilliant violet -421).  
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Isotype Subclass Manufacturer Clone 
APC mouse IgG1k Miltenyi Biotec IS5-21F5 
APC mouse IgG1k BD Pharmingen MOPC-21 
BV421 mouse IgG1k BD Horizon X40 
BV421 mouse IgG1k Biolegend MOPC-21 
PE mouse IgG1k BD Pharmingen MOPC-21 
PE mouse IgG1k Miltenyi Biotec IS5-21F5 
FITC mouse IgG1k BD Pharmingen MOPC-21 
FITC mouse IgG1k Miltenyi Biotec IS5-21F5 
PerCP-Cy5.5 mouse IgG1k BD Pharmingen MOPC-21 
PerCP-Cy5.5 mouse IgG2a, k BD Phosflow MOPC-173 
PEVIO770 
mouse IgG1k Miltenyi Biotec IS5-21F5 
 
Table 4: Isotypes used for flow cytometry  
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Reagent Activity Company Dilution 





DNA stain Life Technologies 1 in 15 
CellTracker™ 
green 











Invitrogen 50 μM 
 
Table 5: Reagents used for flow cytometry 
Zombie is a dead cell discriminator that binds to the N-terminus of proteins. Propidium 
Iodide is a DNA intercalating agent used to analyse DNA content. Cell tracker 
green/violet is a fluorescent dye used to label cells.  
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2.7 Western Blotting 
2.7.1 Cell Lysate Preparation 
Cells were harvested and washed in ice-cold PBS (300 x g for 5 minutes) 
before being lysed with ice-cold RIPA buffer (150mM NaCl, 10mM Tris pH 7.2, 
0.1% SDS, 0.1% Triton-X, 1% deoxycholic acid, 5mM EDTA) containing 
cOmplete™ Mini EDTA-free protease inhibitor cocktail (Roche) and PhosStop 
(Roche) phosphatase inhibitor (1 x 10
6
 cells/50 µL). Lysates were incubated 
on ice for ~30 minutes and stored at -20°C until used. On the day of use, 
lysates were thawed and 5X Laemmli buffer (65.8mM Tris pH6.8, 26.3% 
glycerol, 2.1% sodium dodecyl sulphate, 0.01% bromophenol blue, 1% β-
mercaptoethanol) was added to lysates followed by heating at 95°C for 10-20 
minutes. Cell lysates contained the same concentration of cells in each 
sample, e.g. 1 x 10
6
/ 60 µL. 
 
2.7.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
TRIS Glycine gels were used throughout with the appropriate percentage gel 
chosen based on the size of the protein to be detected. Resolving gel: 
10%,12% or 15% acrylamide, 0.375M Tris pH8.8, 0.1%S DS, 0.1% APS, 
0.001% TEMED. Stacking gel: 6% acrylamide, 0.140M Tris pH6.8, 0.1% SDS, 
0.1% Aps, 0.001% TEMED. The gel cassette was placed into an 
electrophoresis tank and submerged in running buffer (25mM Tris, 192mM 
glycine, 0.1% SDS). Equal volumes of cell lysates for each treatment were 
loaded into individual sample wells and a molecular weight marker (SeeBlue 
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PLus2, Thermo Fisher Scientific) was loaded into a separate sample well; a 
potential voltage difference of 120V was applied for ~1 hour 30 minutes.  
 
2.7.3 Western transfer  
The proteins were transferred from the gel to a Hybond-P polyvinylidene 
fluoride (PVDF) membrane (GE Healthcare Life Sciences) using a semi-dry 
transfer machine (BioRad). The membrane was activated in methanol for ~30 
seconds, the membrane and the gel were then sandwiched between transfer 
buffer (25mM Tris, 192mM glycine, 20% methanol) soaked filter papers. A 
potential voltage difference of 15V was applied for 1 hour.  
 
2.7.4 Antibody Staining 
Membranes were incubated in blocking buffer (1X Tris buffered saline [25 mM 
Tris base, 134 mM sodium chloride, pH 7.5] with 0.1% Tween-20 and 5% 
BSA) for 1 hour at RT or overnight at 4˚C, with continuous agitation. The 
blocking buffer was discarded and replaced with primary antibody (diluted in 
blocking buffer) and incubated overnight at 4°C with continuous agitation. The 
primary antibody was removed and the membrane washed in 1X Tris buffered 
saline with 0.1% Tween (TBST) for 5 minutes, repeated twice. The secondary 
antibody (diluted in blocking buffer) was then added and incubated at RT for 
1 hour, with continuous agitation. The secondary antibody was removed and 
the membrane washed (as above) before pipetting enhanced 
chemiluminescence solution (Amersham™ ECL Prime [GE Healthcare Life 
Sciences] or Clarity™ western ECL substrate [Bio Rad]) over the membrane 
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for ~ 1 minute. The membrane was then sealed in transparent plastic, 
transferred to a light tight X-ray film cassette and exposed onto ECL Hyperfilm 
(GE Healthcare) in a dark room. The film was then developed using a Konica 
SRX-101A tabletop X-ray Film Processor (Konica). Exposure times vary 
depending on the strength of signal  
Antibody Host species Manufacturer dilution 
pStat3
y705
 Mouse Cell signalling technologies 1 in 2000 
Stat3 Mouse Cell signalling technologies 1 in 1000 
β-Actin Mouse Sigma-Aldrich 1 in 1000 
pS6 
s240/244
 Rabbit Cell signalling technologies 1 in 1000 
Puromycin Mouse Merck 1 in 10,000 
Granzyme b Mouse BD Pharmingen 1 in 1000 
Anti-Rabbit HRP Goat Cell Signalling Technologies 1 in 5000 
Anti-Mouse HRP Horse Cell Signalling Technologies 1 in 10,000 
 
Table 6: Antibodies used for Western Blotting 
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2.8 Proteome Profiler Human Phospho-Kinase Array Kit (R&D systems) 
2.8.1 Sample preparation 
1.5 x 10
7
 isolated NK cells were stimulated with cytokines for 60 minutes. Cells 
were transferred to centrifuge tubes, centrifuged at 300 x g for 5 minutes, 
washed in PBS at 300 x g for 5 minutes and finally resuspended in 400 μL 
“lysis buffer 6” (3.75 x 10
7
/mL) and transferred to microcentrifuge tubes. 
Lysates were incubated at 4˚C for 30 minutes with constant agitation then 
centrifuged at 14,000 x g for 5 minutes. Supernatants were transferred to a 
clean microcentrifuge tubes and stored at -80˚C until used.  
 
2.8.2 Assay procedure 
334 μL of lysate were diluted to a final volume of 2 mL with array buffer 1. The 
assay was performed following the manufacturer’s instructions. Multiple 
exposure times (1 minute, 3 minutes, 5 minutes, 10 minutes and 60 minutes) 
using a light tight X-ray film cassette and ECL Hyperfilm (GE Healthcare) were 
developed in a dark room using a Konica SRX-101A tabletop X-ray Film 
Processor (Konica). Analysis was performed using “protein array analyzer” 
plugin for ImageJ.  
 
2.9 Enzyme Linked Immunosorbent Assay 
Human tumour necrosis factor (TNF) ELISA set (BDOptEIA, BD Bioscience) 
was used to quantify levels of secreted TNF in cell culture supernatants 
according to the manufacturer’s instructions. PBMCs were isolated and 
stimulated as previously described before harvesting the supernatants, 
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PBMCs were transferred to a falcon tube and centrifuged for 5 mins at 300 x 
g, the supernatants were carefully pipetted into Eppendorf tubes and frozen 
at -20°C. In brief, 96 well plates (Nunc™ MicroWell™ 96-Well Microplates) 
were coated with 1:250 dilution of Anti-human TNF in 0.1M NaHCO3 pH8.2 
(capture antibody: coating buffer solution) and incubated overnight at 4°C. 
The solution was discarded and the plates were washed three times with 
ELISA wash buffer (PBS + 0.05% tween) and blocked with ELISA assay 
diluent (PBS + 10% FBS pH7) at RT for 1 hour. The assay diluent was 
discarded and the plates were washed again with ELISA wash buffer three 
times. Recombinant human TNF standards of known concentrations (500 
pg/mL – 0 pg/mL) were prepared and loaded into the wells in triplicate. The 
samples were then loaded into the wells in triplicate and incubated at RT for 
2 hours in a sealed plate. The standards and samples were discarded and the 
plate was washed five times in ELISA wash buffer. Detection antibody (1:250 
biotinylated anti-human TNF in ELISA assay diluent) and enzyme reagent 
(1:250 streptavidin-horseradish peroxidase conjugate in detection antibody) 
was added and incubated in a sealed plate at RT for 1 hour. The solution was 
discarded and the plates was washed 7 times in ELISA wash buffer before 
adding the substrate solution (Tetramethylbenzidine (TMB) and Hydrogen 
Peroxide) (BD Pharmingen™) and incubating at RT for 30 minutes, protected 
from light. The reaction was stopped by adding 50 µL 2N H2SO4 and the plate 
was read at 450nm using a Multiskan EX plate reader (Thermo Fisher).  
To quantify human interferon-gamma (IFN-γ) ELISA, Human IFNγ 
ELISA set (BDOptEIA, BD Bioscience) was used according to the 
manufacturers protocol. For the IFN-γ ELISA, the protocol followed was the 
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same (as above) with minor changes. The pH of the coating buffer was 
changed to pH9.5, and antibodies and recombinant standards were Anti-
human IFN-γ. Supernatants from PBMCs and NK cells were harvested after 
cytokine stimulation and frozen at -20˚C until used. 
 
2.10 Realtime PCR 
2.10.1 RNA extraction 
RNA was extracted from Isolated NK cells using RNeasy plus kit (Qiagen) 
according to the manufacturer’s instructions. The cells were harvested into 
centrifuge tubes and pelleted at 300 x g for 5 minutes and washed in PBS at 
300 x g for 5 minutes. The cells were then lysed in the supplied lysis buffer 
(RLT buffer) and 1 volume of ethanol was added to the lysate. The lysate was 
then transferred to a spin column and centrifuged followed by sequential 
centrifuging steps with the supplied wash buffers (as in the protocol). 30 μL of 
RNase-free water was then added directly to the spin column membrane and 
centrifuged to elute the RNA. 1 µL of the RNA was used to determine the RNA 
concentration and purity was determined using a Nanodrop 
Spectrophotometer (Thermo Fisher Scientific), eluted RNA was frozen at  
-80°C. RNA was considered ‘pure’ enough to use when the ratio of the UV 
absorbance at 260nm/280nm was between 1.7 and 2.1. 
 
2.10.2 cDNA synthesis 
50-100 ng total RNA was reverse transcribed using SuperScript™III 
(Invitrogen) according to the manufacturers protocol. 1 μL of Random Primer 
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Mix (New England Biolabs) and 1 µL of dNTPs (Invitrogen) were combined 
with RNA/water to a final volume of 13 µL per reaction. Each reaction was 
heated at 65°C for 5 minutes before placing on ice for >1 minute. 4 µL of 5x 
first-strand buffer (Invitrogen), 1 µL of 0.1M DTT (Invitrogen), 1 µL 
SuperScript™III and 1 µL RNAse-OUT™ (Invitrogen) was added to each 
reaction (final volume 20 µl) before transferring into PCR tubes and placing in 
a thermocycler (Applied Biosciences). Reactions were then incubated at 25°C 
for 5 minutes, 50°C for 60 minutes then 70°C for 15 minutes. cDNA was frozen 
at -80°C until used.  
 
2.10.3 Realtime PCR/TaqMan 
Real-Time PCR (RT-PCR) was performed using QuantStudio® 5 (Applied 
Biosystems) and prepared in microAmp fast optical 96 well reaction plates 
(Applied Biosystems).  Each 20 μL reaction contains 10 μL TaqMan® 
universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems), 8 μL 
nuclease-free water, 1 μL cDNA and 1 μL specific primers (Table 7). 
Reactions were performed in triplicate using the following conditions: 95˚C for 
10 minutes, followed 40 cycles of 95˚C (15 seconds) and 60˚C (1 minute). 
Cycle threshold (Ct) values were automatically generated and expression was 
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Gene Supplier Assay ID Dye Amplicon length 
18s Thermo Scientific Hs03003631_g1 FAM-MGB 69 
GZMB Thermo Scientific Hs00188051_m1 FAM-MGB 114 
IFNG Thermo Scientific Hs00989291_m1 FAM-MGB 73 
 
Table 7: TAQMAN probes 
 
2.11 Statistical analysis 
All statistical analyses were performed using Prism7 GraphPad software. 
Unless otherwise stated, data was analysed using repeated measures two-
way ANOVA with Tukey’s correction for multiple comparisons. In all graphs, 
data are represented as individual donors with standard error of the mean 
(SEM) error bars; within individual graphs, coloured data points correspond to 
the same donor across treatments. 
 
2.12 Ethical Statement 
PBMCs and NK cells were isolated from NC24 leukocyte cones, a waste 
product of platelet donations classed as ‘donated material surplus to clinical 
requirement or unsuitable for therapeutic use’ and issued by the NHS blood 
and transplant service under ‘non-clinical issue for research purposes’. 
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Chapter 3 
Modulation of natural killer cell effector function by 
interleukin 10 
3.1 Introduction 
Interleukin 10 (IL-10) is most frequently described as an anti-inflammatory 
cytokine due to its ability to suppress pro-inflammatory cytokine production 
and inhibit antigen presentation (Couper et al., 2008). Aberrant IL-10 
expression is associated with a variety of autoimmune and inflammatory 
diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and 
psoriasis; however, the activity of IL-10 in these diseases is complex. 
Reduced IL-10 levels are characteristic of inflammatory diseases such as 
psoriasis (Al-Robaee et al., 2008), but paradoxically, patients with rheumatoid 
arthritis show overexpression of IL-10 and elevated serum IL-10 is associated 
with disease severity (Hernández-Bello et al., 2017). IL-10 is a good candidate 
to be targeted therapeutically as it contributes to the pathology of a number of 
diseases. However, IL-10 therapy has shown limited success to date; whilst 
recombinant IL-10 therapy has shown efficacy in psoriasis (Asadullah et al., 
1998), use in IBD has failed to show any beneficial effects in humans (Marlow 
et al., 2013), with one study reporting increased systemic inflammation (Tilg 
et al., 2002). This dichotomy can also be seen in the context of the tumour 
microenvironment. Immunosuppressive cytokines such as IL-10 are prevalent 
in many tumours and are usually reported to promote tumour growth and 
suppress immunity (Sharma et al., 1999, García-Hernández et al., 2002, Vahl 
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et al., 2017); however, some studies report beneficial effects of IL-10 
treatment in cancer (Oft, 2014, Mumm et al., 2011, Tanikawa et al., 2012, Fujii 
et al., 2001, Emmerich et al., 2012). It is clear that the role of IL-10 in 
autoimmune/inflammatory diseases and cancer is both controversial and 
complex.  
Although it is predominantly described as immunosuppressive, IL-10 
can have pro-inflammatory properties in a variety of different cell types, 
including NK cells. Previous data regarding the role of IL-10 on NK cell biology 
is somewhat ambiguous, with data varying between human NK cells, murine 
NK cells and NK-like cell lines. Whilst the use of cell lines is invaluable for 
research, cell lines such as NK-92 require the presence of IL-2 for survival. 
As IL-2 is a potent activating cytokine for both T cells and NK cells (Wang et 
al., 1999), these cells are already primed/activated and are therefore not a 
good candidate for studying the activation potential of cytokines. Additionally, 
there are several immunological differences between human and murine 
models that may impact the effect of cytokine stimulation, such as receptor 
structure and expression (Mestas and Hughes, 2004). Data from human NK 
cells seem to support an immunostimulatory role of IL-10 in NK cells; however, 
previous studies detail varied responses to IL-10 in combination with different 
cytokines, along with contradictions from in vivo and in vitro studies. 
Experiments detailed in this chapter aim to confirm the activity of IL-10 on 
human primary NK cells, negating problems with cell lines or inter-species 
variation, and investigate the mechanisms that mediate these.  Here I have 
explored how IL-10 effects the main NK cell activities, cytotoxicity and cytokine 
production.  
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3.2 IL-10 inhibits production of pro-inflammatory cytokines from PBMC 
For the assays described I have used a commercial source of IL-10 (Table 2). 
To verify the activity of IL-10, I used a well-established assay in which 
Lipopolysaccharide (LPS)-induced TNFα production from macrophages is 
suppressed by IL-10. The outer wall of gram negative bacteria (such as E.coli 
and Salmonella) contains LPS (also known as endotoxin), a potent activator 
of innate immunity and ligand for the TLR4-MD2 complex, expressed on 
monocytes, macrophage and DC (Guha and Mackman, 2001, Kaisho et al., 
2001). Engagement of LPS by TLR4-MD2 and the co-receptor CD14 induces 
a signalling cascade resulting in the release of NF-κB from IκB and 
subsequent translocation of NF-κB to the nucleus, where it induces 
transcription of target genes, including TNFα (Lu et al., 2008). The anti-
inflammatory action of IL-10 on monocytes/macrophages includes the ability 
to suppress LPS-mediated induction of TNFα release, which can be used to 
determine IL-10 specific activity. PBMCs were cultured in the presence of LPS 
± IL-10 for 16 hours before harvesting the supernatants for analysis. The 
results shown in Figure 6A and B indicate that TNFα production was strongly 
induced by LPS stimulation and that IL-10 reduced TNFα production in a 
dose-dependent manner (Figure 6B). The recombinant source of IL-10 
therefore effectively inhibits LPS-induced TNFα production from PBMCs and 
importantly, validated the activity of the IL-10 used in this work.  
These data demonstrate that IL-10 has potent immunosuppressive 
actions on PBMCs in a mixed population. However, this assay does not 
delineate the activity of IL-10 on individual cell types. In mixed cell populations 
such as PBMCs, cells respond to both direct cytokine stimulation, and 
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indirectly through secondary secreted molecules or via cell-to-cell contacts. In 
order to determine whether NK cells are directly modulated by IL-10, 
subsequent assays were performed using isolated NK cells. Although this 
type of analysis may not account for the complexity of an immune response 
with multiple interacting cell types, the direct effect of IL-10 on NK cells and 
the molecular mechanisms of action will be interrogated.  
 
 
Figure 6: TNF-α production is inhibited by IL-10 
PBMC’s were stimulated with 100 ng/mL LPS ± 20 ng/mL IL-10 for 16 hours;  TNF-α 
production was determined using ELISAs. (A) Graphs show mean concentration of 
TNF-α; each dot represents the mean of a triplicate measurement from a single donor 
(n=5), and (B) mean of triplicate measurements from one experiment (n=1), 
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3.3 NK cells express a functional IL-10 receptor  
IL-10 signals via the IL-10 receptor, IL-10R (also known as CD210). To 
determine IL-10R expression on NK cells and their ability to signal via IL-10, 
NK cells were identified within a mixed population of PBMCs and IL10R 
expression was interrogated using flow cytometry (Figure 7A and B). 
Lymphocytes were identified and gated on based on their forward scatter 
(FSC) and side scatter (SSC) parameters (measures of cell size and 





 cells; expression of IL-10R was then determined (Figure 7C-E). 
Analysis showed that cell surface expression of IL-10R was variable between 
donors, however, all donors demonstrated a high percentage of NK cells that 
were positive for IL-10R (>60%; Figure 7D). IL-15 is the prototypical NK cell 
activating cytokine, and has been shown to alter NK cell surface expression 
of a multiple receptors (Wilson et al., 2011). However, stimulation with either 
50 ng/mL IL-10 or 20 ng/mL IL-15 did not significantly alter the percentage of 
NK cells expressing IL-10R (Figure 7D) or the density of IL-10R expression 
(Figure 7E). These data indicate that NK cells have the potential to be 
regulated by IL-10.  
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Figure 7: NK cells express the IL-10 receptor 
NK cells were evaluated for IL-10R expression by flow cytometry after being 
stimulated with 50 ng/mL IL-10 or 20 ng/mL for 48 hours. (A) Lymphocytes were 
identified from the PBMC population based on FSC and SSC gating. (B) 









 population. (C) NK cells were further analysed for IL-
10R expression. Representative histograms show IL-10R expression to the right of 
the isotype bar (black line) set at 2% of the isotype control. (D) Graphs show the 
percentage of NK cells positive for IL-10R expression, and (E) the median fluorescent 
intensity (MFI) of expression (fold change relative to untreated cells) (n=4). 









































































































 - 76 - 
3.4 NK cells treated with IL-10 activate the JAK-STAT pathway 
The most intensively studied and frequently reported IL-10 signalling pathway 
is the JAK1/STAT3 pathway (Qayum et al., 2016, Niemand et al., 2003, 
Rodríguez-Bayona et al., 2013). IL-10/IL10R interactions induce JAK1 and 
TYK2 activity that subsequently induce the downstream phosphorylation of 
STAT3 at tyrosine residue 705 (pSTAT3
Y705
) (Glocker et al., 2011) (Figure 3). 
To confirm signalling via IL-10R in NK cells, phosphorylation of STAT3
Y705
 
was analysed. Isolated NK cells were treated with increasing concentrations 
of IL-10 for 30 minutes, and the expression of phospho-STAT3
Y705
 was 
determined by western blotting. IL-10 stimulation (0.5 – 500 ng/mL) induced 
the phosphorylation of STAT3 in a dose dependent manner (Figure 8A), whilst 
total STAT3 expression remained unchanged by the addition of IL-10. 
Stimulation with 50 ng/mL for 30 minutes resulted in detectable pSTAT3
 Y705
 
expression that was maintained at 48 hours (Figure 8B); these results confirm 
that IL-10 induces activation of the STAT3 signalling pathway in NK cells.  
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Figure 8: IL-10 signals via STAT3 in NK cells 
(A) Isolated NK cells were stimulated with increasing concentrations of IL-10: 0.5 
ng/mL, 5 ng/mL, 50 ng/mL and 500 ng/mL, for 30 minutes prior to lysis and analysis 
by western blot for pSTAT3
Y705
 expression. Total STAT3 and β-actin were probed for 
as loading controls (n=1). (B) Isolated NK cells were either untreated or stimulated 
with 50 ng/mL IL-10 for 30 minutes or 48 hours prior to lysis and western blot analysis 
for pSTAT3
Y705
 expression (total STAT3 was probed for as a loading control) 
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3.5 IL-10 upregulates Granzyme B expression in NK cells 
Unlike T cells, which require antigen stimulation to trigger the synthesis of 
cytotoxic components, NK cells constitutively express cytolytic granules. This 
enables a rapid response against infected cells and tumours, providing killer 
cell activity whilst T cells become armed. The cytotoxic granules of NK cells 
contain the five granzyme molecules, A, B, H, K and M and perforin, a pore 
forming molecule that allows granzymes to enter the target cell (Ewen et al., 
2012, Lopez et al., 2013). Granzyme B is the most abundant and intensively 
studied granzyme molecule and plays a key role in the induction of target cell 
apoptosis (Chowdhury and Lieberman, 2008). Granzyme B is constitutively 
expressed by NK cells (Kai et al., 2005) and further induced upon NK cell 
activation by target cells or activating cytokines such as IL-2, IL-12, IL-15 and 
IL-18 (Liu et al., 2002). To determine the effect of IL-10 on primary NK cell 
cytolytic functions, granzyme B expression was analysed at the mRNA and 
protein level. NK cells were stimulated with IL-15 (as a positive control) or IL-
10 for 48 hours and analysed by western blot and flow cytometry. Both 
methods detected granzyme B expression in unstimulated NK cells, and this 
was upregulated by IL-15 (Figure 9) as reported previously (Wilson et al., 
2011). In these assays, IL-10 also upregulated granzyme B expression at both 
the mRNA and protein level. Western blot analysis showed IL-10 upregulated 
granzyme B protein levels comparable to that induced by IL-15 (Figure 9A and 
C). Flow cytometry confirmed the upregulation of expression of granzyme B 
although the extent of upregulation was reduced compared to that seen by 
western blotting (Figure 9B). All assays consistently demonstrated an 
increase in granzyme B expression in response to IL-10. The induction of 
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granzyme B protein by IL-10 was mirrored by an increase in GZMB mRNA 
following IL-10 treatment (Figure 9D). Furthermore, mRNA and western 
blotting show that the combination of IL-10 and IL-15 induced greater levels 
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Figure 9: Granzyme B expression in cytokine stimulated NK cells 
NK cells were stimulated with 50 ng/mL IL-10, 20 ng/mL IL-15 or both for 48 hours 
before analysis by (A) western blot with β-actin probed for as a loading control 
(representative of n=4) or (B) intracellular flow cytometry (n=1); grey histogram = 
isotype, black = untreated, green = IL-10, red = IL-15 and blue = IL-10 + IL-15. (C) 
Densitometry analysis was performed using ImageJ on 3 individual experiments, β-
actin was used as a loading control and values are expressed as a fold change from 
untreated (n=3). (D). qRT-PCR for granzyme B mRNA transcripts was performed on 
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3.6 IL-10 enhances NK cells degranulation  
Granzyme B expression is an indicator of cytolytic potential, however the 
observed increased in granzyme B expression does not illuminate whether it 
is the number of granules, or the content of the granules that is increased. 
Recent studies concerning the kinetics of NK cell degranulation have found 
that the size and content of the lytic granules influences the efficiency of target 
cell death. Whilst the NK cell lines YTS and NK92 contained similar numbers 
of lytic granules, YTS induced target cell death faster than NK92, an 
observation that was attributed to the larger granule size containing more 
effector molecules (Gwalani and Orange, 2018). The fact that IL-10 and IL-15 
increase granzyme B expression suggests that they either have more 
granules, enabling them to kill more target cells, or increased granule content 
to improve target cell death efficiency. In order for increased granzyme B 
expression to contribute to cytolytic activity, NK cells must first exocytose the 
lytic granules across an immunological synapse. Measuring the level of 
granule exocytosis provides a more detailed picture of NK cell responses than 
measuring target cell death alone. Degranulation can be measured with a flow 
cytometric assay that analyses the expression of CD107a (LAMP-1) on the 
NK cell surface. CD107a is a granule membrane associated protein that is 
transiently displayed on the cell surface during degranulation, allowing for the 
detection of NK cells that have degranulated (Aktas et al., 2009).  
 NK cells were stimulated with IL-10 or IL-15 for 48 hours prior to being 
co-cultured with target cells in the presence of an intracellular protein transport 
inhibitor (GolgiStop) to prevent recycling of the lysosomal proteins from the 
NK cell surface. NK cells were analysed for cell surface expression of 
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CD107a, NK cells cultured alone ± cytokines were used as a control to 
measure the basal expression level of CD107a on the cell surface. Two target 
cell lines were used, K562 and SKOV3. K562 (derived from a myeloid 
leukaemia) is a well-established NK target cell line that expresses low levels 
of MHC I and therefore provides a strong activating stimulus to NK cells 
(Lozzio, 1975). SKOV3 is an ovarian cancer cell line shown to be less 
sensitive to NK cell lysis (Kruschinski et al., 2008). In the presence of K562, 
48% of unstimulated NK cells degranulated, compared to only 5% in the 
presence of SKOV3 (Figure 10B and C). As expected, regardless of target 
cell, IL-15 stimulated NK cells degranulated more readily, with 68% of NK cells 
expressing CD107a in the presence of K562 (1.4-fold increase) and 18% in 
the presence of SKOV3 (3.6-fold increase). Interestingly, IL-10 stimulation 
also induced NK degranulation towards both targets, with 61% against K562 
(1.25-fold increase) and 13% against SKOV3 (2.6-fold increase) (Figure 10B 
and C). The simultaneous addition of both IL-10 and IL-15 stimulation did not 
increase degranulation above IL-15 alone when co-cultured with K562 (67%) 
but did show an additive effect against the SKOV3 target (29%) (Figure 10B 
and C). When comparing untreated NK cells with IL-10 stimulated NK cell 
degranulation, a greater percentage of IL-10 stimulated NK cells degranulated 
towards target cells (K562 [p=0.0001]); SKOV3 [p=0.0551]) (Figure 10D and 
E).
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Figure 10: NK cell degranulation 
NK cells were stimulated with 50 ng/mL IL-10, 20 ng/mL or both for 48 hours before being co-cultured with cell tracker violet (CTV) labelled K562 or SKOV3 
target cells at 1:1 (E:T). Co-cultures were analysed by flow cytometry, CTV negative (CTVneg) NK cells were gated on and analysed for expression of CD107a. 
(A) Representative histograms from one donor. (B) Graphs show mean % CD107a+ NK cells against K562 (n=3) or (C) SKOV3 (n=2). (D) Graphs show 
CD107a+ untreated NK cells vs. NK cells stimulated with IL-10 against K562 (n=8) or (E) SKOV3 (n=3) (data shown in D and E are from the untreated and 
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3.7 IL-10 stimulated NK cells induce target cell death 
In similar co-culture assays, target cell death can be also be measured to 
determine NK cell cytolytic activity. NK cells were stimulated, as in the 
degranulation assays, prior to being co-cultured at effector to target ratios 
(E:T) of 1:1 or 5:1 with K562 target cells. After incubation, cell death was 
determined with the use of a dead cell discriminator (Zombie NIR™) and 
analysed by flow cytometry. Both IL-10 and IL-15 stimulated NK cells induced 
more target cell death than untreated NK cells. IL-10 stimulation resulted in 
2.2 - 2.5-fold increase in cell death and IL-15 stimulation resulted in 3.4 - 5-
fold increase at E:T 1:1 and 5:1, respectively (Figure 11C and D). The 
combination of IL-10 and IL-15 stimulation did not enhance target cell death 
more than IL-15 alone at the lower E:T ratio; however, the data suggests an 
additive effect at the higher E:T ratio resulting in 10% more cell death than IL-
15 alone (Figure 11D). When comparing target cell death induced by 
untreated NK cells vs. IL-10 stimulated NK cells, IL-10 stimulated NK cells 
induced a greater percentage of target cell death (p=0.0004) (Figure 11E).  
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Figure 11: NK cell induced target cell death 
NK cells were treated for 48 hours with 50 ng/mL IL-10, 20 ng/mL IL-15 or both prior 
to being co-cultured with CTV labelled K562 target cells at 1:1 and 5:1 E:T. After 
incubation, the co-culture was stained with a dead cell discriminator (Zombie NIR™) 
and analysed by flow cytometry to measure target cell death. (A) Representative 
gating strategy (1:1); target cells were identified as CTV+ and effectors as CTVneg 
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NIR™ fluorescence (bottom panel). (B) Representative histograms of from one donor 
of target cells co-cultured with IL-15 stimulated NK cells (gated as in panel A). (C) 
Graphs show mean target cell death at 1:1 and (D) 5:1 (n=3). (E) Graphs show mean 
target cell death with untreated NK cells vs. NK cells stimulated with IL-10 (n=10) 
(data shown in these graphs are from the untreated and IL-10 treatment groups in 
several assays in this thesis to increase the n number).  
*** P=<0.001, determined using a paired t-test (Figure 11E). 
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3.8 IL-10 does not enhance IFN-γ secretion 
As well as having potent cytotoxic activity, activated NK cells produce pro-
inflammatory cytokines such as IFN-γ (Caligiuri, 2008b), allowing activated 
NK cells to interact with other cell types and regulate immune responses. NK 
derived IFN-γ is essential for priming of Th1 cell responses in lymph nodes 
(Martín-Fontecha et al., 2004) and for the differentiation of monocytes into 
macrophages and DCs at sites of infection (Goldszmid et al., 2012). To further 
investigate the functional consequences of IL-10 signalling, IFN-γ production 
was analysed. PBMCs were stimulated with IL-15 ± IL-10 or IL-1β ± IL-10 for 
48 hours and supernatants analysed by ELISA for IFN-γ. Treatment with IL-
1β or IL-15 induced similar levels of IFN-γ (Figure 12A); however, combination 
treatments with IL-10 showed diverse effects. In combination with IL-1β, IL-10 
displayed anti-inflammatory activity by inhibiting the production of IFN-γ, but 
interestingly, IL-10 did not inhibit IL-15 induced IFN-γ production (Figure 12A). 
Using PBMCs and ELISA assays, it is not possible determine which cell type 
IL-1β is stimulating, or the source of IFN-γ. Many immune cells are capable of 
producing IFN-γ; however, the predominant innate immune cell source is NK 
cells (Thäle and Kiderlen, 2005, Abboud et al., 2016, Uemura et al., 2009). IL-
1β is a potent activator of the NF-κB pathway which induces the secretion of 
many pro-inflammatory cytokines, including the cytokine IL-12 (formerly 
known as NK cell stimulating factor) (Kobayashi et al., 1989). Additionally, IL-
1β requires co-stimulation with IL-12 for the production of IFN-γ in NK cells 
(Cooper et al., 2001). Therefore, in the experimental model used here, IL-1β 
is most likely stimulating IL-12 (or IL-18) secretion from mononuclear cells that 
further stimulates IFN-γ secretion from NK cells. Presumably, IL-10 inhibits IL-
 - 88 - 
12 release from monocytes and hence indirectly reduces IFN-γ production by 
NK cells. This demonstrates the classical IL-10 activity, suppressing the 
synthesis of pro-inflammatory cytokines from monocytes. Unexpectedly, the 
addition of IL-10 to IL-15 stimulated PBMCs did not suppress IFN-γ secretion. 
Unlike the marked reduction observed in the IL-1β/IL-10 stimulation, the 
presence of IL-10 had no effect on the ability of IL-15 to induce IFN-γ secretion 
(Figure 12A). IL-15 directly activates NK cells, suggesting that IL-10 does not 
directly inhibit NK cells. Although IL-10 inhibits IFN-γ secretion after IL-1β 
stimulation, this is presumably indirectly by suppressing the production of 
other pro-inflammatory cytokines from other cell types. The presence of IL-10 
in these assays demonstrate the pleiotropic effects of IL-10 in response to 
different stimuli and presumably on different cell types.  To investigate 
this further, isolated NK cells were stimulated with IL-12 + IL-18 (potent 
inducers of IFN-γ (Chaix et al., 2008)) ± IL-10 for 48 hours before analysing 
the supernatant for IFN-γ; IL-12 + IL-18 stimulation induced an abundance of 
IFN-γ from NK cells that was not inhibited by the presence of IL-10 (Figure 
12B), confirming that IL-10 does not directly inhibit IFN-γ production from NK 
cells. Similar to PBMCs stimulated with IL-10, isolated NK cells stimulated with 
IL-10 did not secrete IFN-γ (Figure 12B). To further understand the role IL-10 
plays in IFN-γ production, I analysed the expression of mRNA from isolated 
NK cells using qRT-PCR. Isolated NK cells were stimulated with IL-10 or IL-
15 for 48 hours. In contrast to IFN-γ protein, IL-10 stimulation upregulated 
IFN-γ mRNA, although to a much lower extent than IL-15 (Figure 12C). 
  It is possible that IL-10 upregulates IFN-γ mRNA without upregulating 
its protein product, and that further signals may be required to induce 
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translation. It is therefore important to determine whether NK cells are 
producing IFN-γ protein in response to IL-10, consequently, another method 
of protein detection was employed to confirm the previous results. To this end, 
intracellular cytokine staining of IFN-γ was performed and analysed using flow 
cytometry.  
 NK cells were stimulated with IL-10 or IL-15 for 48 hours, Golgi stop 
was then added to the culture for 4 hours before cells were fixed, 
permeabilised and analysed for IFN-γ expression. Only a very low percentage 
of unstimulated NK cells expressed IFN-γ and this was enhanced by IL-15 
stimulation. However, IL-10 stimulation did not upregulate IFN-γ expression 
compared to the untreated control (Figure 13A and B). In agreement with the 
ELISA, IL-10 did not inhibit IL-15 mediated IFN-γ upregulation (Figure 13A 
and B). To understand whether a second signal was required to translate the 
IFN-γ mRNA into protein, NK cells were pre-stimulated with IL-10 or IL-15 
before being co-cultured with K562 and analysed for IFN-γ expression as 
described above (Figure 13A and C). The presence of K562 increased the 
percentage of IFN-γ+ NK cells, but stimulation with IL-10 did not enhance this 
when compared to the untreated control. IL-15 stimulation greatly enhanced 
the expression of IFN-γ and, as with NK cells alone, IL-10 did not inhibit IL-15 
induced IFN-γ expression (Figure 13A and C). Although IL-10 upregulated 
IFN-γ mRNA, it was not possible to detect upregulated protein expression or 
secretion from NK cells. However, it should also be noted that whilst IL-10 did 
not enhance IFN-γ production, IL-10 did not inhibit the expression or secretion 
of IFN-γ from IL-15 stimulated NK cells.
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Figure 12: NK cell IFN-γ production is not inhibited by IL-10 
 (A) PBMCs were stimulated with IL-15 (20 ng/mL) +/- IL-10 (50 ng/mL), IL-1β (10 
ng/mL) ± IL-10 for 48 hours prior to being analysed by ELISA for IFN-γ (n=4). (B) NK 
cells were stimulated with IL-12 (1 ng/mL) and IL-18 (5 ng/mL) ± IL-10 (50 ng/mL) for 
48 hours prior to be analysed by ELISA for IFN-γ (n=3). Graph shows fold change 
from untreated control. (C) cDNA was synthesized from NK cells that were stimulated 
with IL-15 (20 ng/mL), IL-10 (50 ng/mL) or both for 48 hours and analysed by qRT-
PCR for IFN-γ mRNA transcripts (n=2). Values were normalised to housekeeping 
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Figure 13: NK cell IFN-γ secretion is not enhanced by IL-10 
NK cells were stimulated with IL-15 (20 ng/mL), IL-10 (50 ng/mL) or both for 48 hours 
prior to being co-cultured 1:1 with K562 for 5 hours. The co-cultures were then fixed 
and permeabilised before being stained with anti-IFN-γ and analysed by intracellular 
flow cytometry. (A) Representative flow cytometry plots. (B) Graph shows percentage 
of IFN-γ+ NK cells in the absence of K562 (n=3), and (C) and IFN-γ+ NK cells in the 
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3.9 Discussion 
The pleiotropic effects of IL-10 have previously been observed across many 
cell types, including NK cells. Various studies detail pro-inflammatory effects 
of IL-10 on NK cells, including enhanced cytotoxicity, increased IFN-γ 
production and the ability to potentiate production of other pro-inflammatory 
cytokines (Carson et al., 1995, Lauw et al., 2000, Cai et al., 1999). However, 
IL-10 has also been shown to have inhibitory effects towards NK cells; Scott 
et al. reported that IL-10 neutralisation enhanced NK cell activation in a murine 
model of bacterial infection (Scott et al., 2006). Investigations into IL-10 
mediated NK cell activity have revealed conflicting data, this could be in part 
down to the source of NK cells (NK-like cell lines vs. primary cells) distinct 
activities in different models (tumour co-cultures, bacterial infections) and the 
differences between in vivo and in vitro systems.  
This study aimed to uncover how IL-10 influences primary human NK 
cells. IL-10 receptor expression is crucial for IL-10 to exert its effect on cells 
and I have confirmed that it is expressed by human NK cells. IL-10 receptor 
expression was initially characterised on NK cells by Carson et al.; this study 
showed that NK cells constitutively expressed the IL-10R at low density and 
this was not altered by IL-2 activation, despite IL-2 treatment resulting in 
downregulation of IL-10R mRNA (Carson et al., 1995). Here I demonstrate 
cell surface expression of IL-10R, which was not significantly altered by either 
IL-10 or IL-15 stimulation.  
The JAK/STAT signalling pathways are of major importance in cytokine 
mediated cellular activity, with many cytokines activating multiple STATs to 
achieve different cellular responses. IL-10 is predominantly reported to 
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activate the STAT3 pathway and that has been confirmed in variety of immune 
cells. Here I have shown that IL-10 stimulation of NK cells induces 
phosphorylation of STAT3 in a dose dependent manner, subsequently 
resulting in enhanced cytotoxicity. It is still unclear whether this is the only 
mechanism of IL-10 activity, or indeed the mechanism responsible for this 
enhanced NK cell activity. Whether STAT3 signalling results in NK cell 
activation or inhibition is debated. Gotthardt et al. show that in a STAT3-/- 
mouse model, NK cell development and maturation are unaltered and tumour 
surveillance is enhanced (Gotthardt et al., 2014). STAT3 depletion resulted in 
increased granzyme B, perforin and DNAM1 expression that contributed to an 
increase in in vitro target cell killing of the melanoma cell line B16F10, and 
prolonged in vivo survival in a v-abl+ leukaemia model. This study 
demonstrates an immunosuppressive role for STAT3 in NK cells; however, 
increased signalling via STAT4 and STAT5 in the absence of STAT3 was also 
observed (Gotthardt et al., 2014). Whilst IL-2/IL-15 and IL-12 are known to 
signal via STAT5 and STAT4, respectively, these activating cytokines are also 
known to mediate their effects via STAT3 (Johnston et al., 1995, Jacobson et 
al., 1995). The deficiency of STAT3 could be compensated for by other STAT 
pathways resulting in stronger signalling, the enhanced cytotoxicity 
demonstrated here could be in part due to higher activity of other STAT 
proteins compensating for the loss of STAT3. In contrast to this, Zhu et al. 
show that the expression of a key NK cell activating receptor, NKG2D, was 
driven by STAT3. NKG2D expression is transcriptionally controlled by STAT3, 
due to a STAT3 binding site in the NKG2D promoter, and that binding is 
enhanced by treatment with IL-10 or IL-21. Cell surface expression and mRNA 
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levels of NKG2D were upregulated by STAT3 activation and could be blocked 
with small molecule inhibitors of STAT3 (Zhu et al., 2014). In addition, this 
study also observes enhanced degranulation of NK cells with activated STAT3 
that was reduced in the presence of STAT3 inhibitors. Reduced NKG2D 
expression was also confirmed in NK cells isolated from haematopoietic 
STAT3-/- mice compared to WT, and the ability of STAT3 activating cytokines 
to increase expression of NKG2D was blunted in hyper-IgE syndrome patient 
samples with dominant negative mutations in STAT3 (Zhu et al., 2014). These 
studies show clear yet distinct roles of STAT3 in NK cell activity. This is not 
unique to NK cells, STAT3 plays multiple roles dependent on cell type and 
stimulus. STAT3 mediates both IL-6 and IL-10 signal transduction to provide 
pro and anti-inflammatory responses respectively in monocytes (Niemand et 
al., 2003), highlighting that this transcription factor is central to many cellular 
activities. It is possible that STAT3 mediates multiple responses in NK cells, 
as it does in monocytes (Niemand et al., 2003). Although knockout models 
provide great insight into the role of STAT3, it would be useful to investigate 
its role in response to different stimuli and understand how one transcription 
factor mediates such diverse outcomes.  
The connection between IL-10 and granzyme B expression has been 
investigated in other studies. As with much of the data concerning IL-10 
activity, these reports show cell type or environment specific activity. Murine 
CD8+ T cells isolated from IL-10 treated tumours were shown to have highly 
upregulated granzyme mRNA expression and the same was observed in 
human CD8+ T cells stimulated in vitro with IL-10 (Mumm et al., 2011). 
Conversely, in the context of hepatocellular carcinoma (HCC), the frequency 
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of granzyme B+ CD4+ T cells were found to negatively correlate with IL-10 
expressing B cells (Bregs). Moreover, when cultured together in vitro, Bregs 
were found to suppress granzyme B expression in CD4+ T cells (Xue et al., 
2016). In vitro stimulation of BCR-engaged B cells with IL-10 in combination 
with IL-4 was found to enhance granzyme B expression in B cells (Hagn et 
al., 2009), and IL-10R blockade reduced the number of granzyme B+ NK cells 
from the lungs and spleen of an MCMV infection model (Stacey et al., 2011). 
These studies exemplify the range of cell types and systems used to 
investigate this relationship, highlight the varied responses, and why it is 
important to assess the effect of IL-10 on granzyme B expression in primary 
human NK cells. The results in this chapter clearly show increased granzyme 
B expression at the mRNA and protein level in response to IL-10. Regardless 
of donor variability, western blotting and FACS analysis showed upregulated 
granzyme B protein expression, and western blotting and qRT-PCR data 
indicate an additive effect of IL-10 and IL-15 in combination. It is possible that 
the combination of cytokines triggers distinct signalling pathways via STAT3 
and STAT5 to induce granzyme B expression, or perhaps both result in strong 
STAT3 signalling or STAT3/STAT5 heterodimers to achieve this. The concept 
of cytokine synergy is well-known and many cytokines work cooperatively to 
determine cell fate/activity. Combinations of cytokines have also been shown 
to enhance other function in NK cells, such as proliferation and IFN-γ 
production (Cai et al., 1999, French et al., 2006). It is interesting to see in this 
study, that IL-10 does not inhibit IL-15 induction of granzyme B, further 
supporting a pro-inflammatory role of IL-10.  
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IL-10 stimulation of NK cells also resulted in enhanced degranulation. 
Interestingly, the combination of cytokines did not indicate an additive effect 
when co-cultured with K562, showing similar levels of degranulation to IL-15 
stimulated cells. However, co-culture with SKOV3 targets showed enhanced 
levels of degranulation following IL-10 treatment. Both K562 and IL-15 are 
potent NK cell activators, in combination these maximally stimulate the NK 
cells and the addition of IL-10 is negated. The weaker stimulation from SKOV3 
targets allows for the additive effect of other activating stimuli, such as IL-10, 
to contribute to overall degranulation. This raises important considerations for 
the environments in which IL-10 could exert pro-inflammatory effects. 
Nevertheless, IL-10 was able to prime NK cells for better degranulation upon 
target contact, whether this is achieved through the same mechanisms as IL-
15 remains to be explored.  
 Increasing the E:T ratio increased target cell death as expected, as 
more NK cells are able to form synapses with the target cells, and this was 
seen in all conditions. However, less target cell death was observed with IL-
10 stimulated NK cells than IL-15 stimulated NK cells regardless of E:T ratio. 
Given that IL-10 increased granzyme B expression and degranulation in a 
similar manner to IL-15, I expected target cell death to be similar in both 
conditions. This suggests that IL-15 induces more degranulation than IL-10. 
Although we can detect degranulation, this method does not provide 
information on the serial killing ability of these cells. It is possible that IL-15 
stimulated NK cells are able to degranulate quicker, or are more capable of 
forming successive synapses than IL-10 stimulated NK cells.  
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 The role IL-10 plays in the control of IFN-γ remains elusive. IFN-γ 
expression and secretion is tightly controlled by an array of epigenetic, 
transcriptional and post-transcriptional mechanisms (Mah and Cooper, 2016); 
NK cells have a constantly accessible IFNG locus and low-level transcription 
of IFN-γ mRNA (Stetson et al., 2003), presumably to allow for rapid induction 
of effector functions. Upregulation of IFN-γ expression is achieved by NKR 
ligation, antibody recognition by CD16 or cytokine stimulation; each of which 
activate distinct transcription factors including MAPK, STATs and NF-κB, that 
can bind promoter and enhancer regions to promote IFN-γ transcription (Mah 
and Cooper, 2016). NK cell recognition of K562 target cells is dependent on 
the engagement of activatory NKRs which induce IFN-γ production. Keppel et 
al. showed that the mechanisms of IFN-γ production are dependent on the 
nature of the stimulus. Whilst both cytokine and NKR stimulation resulted in 
increased protein production, IL-12/IL-18 stimulation highly upregulated IFN-
γ mRNA whereas only modest changes were seen with NKR stimulation, 
indicating that the transcription and translation of IFN-γ are independently 
controlled. This suggests that IFN-γ production by cytokine stimulation is 
transcriptionally controlled, whereas NKR stimulation was post-
transcriptionally controlled (Keppel et al., 2015). Here I have shown that NKR 
engagement (by addition of K562 target cells) upregulates IFN-γ protein in the 
absence of cytokine stimulation and this was enhanced in IL-15 stimulated NK 
cells. IL-15 stimulation enhanced IFN-γ protein regardless of NKR 
engagement, indicating that IL-15 regulates both transcriptional and 
translation pathways. IL-10 stimulation induces mRNA but not protein 
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expression, suggesting that IL-10 does not activate pathways required for 
IFN-γ translation.  
 More recently, the metabolic requirements of NK cell activation have 
been investigated (Mah et al., 2017, Keppel et al., 2015, Keating et al., 2016, 
Donnelly et al., 2014). Blocking oxidative phosphorylation (OXPHOS) 
inhibited IFN-γ production from NKR stimulated NK cells, identifying 
respiration as essential to induce IFN-γ production after NKR stimulation. This 
inhibition was not observed in NK cells stimulated with IL-12/IL-18, revealing 
OXPHOS independent IFN-γ production. Interestingly, stimulation with IL-
12/IL-15 was partially impaired by OXPHOS blockade, suggesting this signal 
is weaker than IL-12/IL-18. However, prolonged high dose IL-15 treatment 
could overcome these metabolic requirements (Keppel et al., 2015). 
Furthermore, IL-2 and IL-12/IL-15 stimulation has been shown to 
metabolically reprogram NK cells by upregulating nutrient receptors (CD71, 
CD98 and GLUT1) and the metabolic regulator mTOR. This reprogramming 
increases the rate of glycolysis and OXPHOS, allowing for biosynthetic 
demands such as IFN-γ production (Keating et al., 2016, Donnelly et al., 
2014). Cellular metabolism has also been shown to regulate cytokine 
production through levels of GAPDH. Whilst the primary role of GAPDH is in 
glycolysis, it has also been shown to repress IFN-γ translation by binding AU 
rich elements (AREs) in the 3’UTR. The metabolic switch from OXPHOS to 
aerobic glycolysis that is observed in activated T cells, increases the 
requirement for GAPDH in glycolysis, therefore relieving GAPDH mediated 
repression (Chang et al., 2013). IL-15 increases the rate of glycolysis in NK 
cells (Keating et al., 2016) and therefore recruits GADPH into the glycolytic 
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pathway, allowing IFN-γ to be translated. It is possible that IL-10 does not 
stimulate glycolysis, therefore GAPDH remains bound to IFNG mRNA and 
represses IFN-γ translation. Aside from metabolism, a possible reason for the 
lack of protein production induced by IL-10 could be explained by unstable 
mRNA transcripts. Many inflammatory mediators have unstable mRNAs due 
to the presence of AREs in the 3’UTR. AREs have been shown to promote 
mRNA degradation through interactions with multiple proteins, providing 
another level of regulation for inflammatory responses (Stumpo et al., 2010). 
IL-12 and IL-18 stimulation has been shown to stabilise IFN-γ mRNA by via 
MAPK p38, and IFN-γ protein production was greatly reduced by p38 inhibition 
(Mavropoulos et al., 2005).  
It should be noted that although many of these experiments were 
performed with isolated NK cells, the nature of negative cell selection does 
not ensure 100% pure NK cells. Therefore, a small percentage of cells in these 
assays are non-NK PBMCs (T cells, B cells or monocytes). As these can 
respond to IL-10 and interact with NK cells (either through cell interactions or 
cytokines), the number of non-NK cells in culture may impact NK cell 
responses. For instance, IL-10 treatment will inhibit the production of pro-
inflammatory cytokines from monocytes but IL-15 will not, meaning a high 
percentage of monocytes in the assays could lead to reduced NK cell 
activation in the IL-10 stimulated groups through indirect monocyte-mediated 
mechanisms. These interactions must be considered when interpreting data 
from these assays; however, as the number of non-NK cells in these assays 
is minimal, these effects will also be minimal.  
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 The aim of the work in this chapter was to confirm the signalling 
pathway used by IL-10 in NK cells, and investigate how this signalling effects 
NK cell function. The data presented confirms that IL-10 signals via STAT3, 
and that IL-10 enhances NK cell cytotoxicity, but does not upregulate IFN-γ 
protein production. Taken together, this data provides strong evidence of a 
pro-inflammatory effect of IL-10 on NK cells. The next chapter of this study 
investigates how IL-10 affects other NK cells activation mechanisms such as 
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Chapter 4 
IL-10 and NK cell activation pathways 
4.1 Introduction 
Activation is an umbrella term used to describe a variety of cellular changes 
that distinguish between unstimulated and stimulated cells. In addition to 
enhanced cytotoxicity, activated lymphocytes can be characterised by altered 
expression of activation receptors (Sanchez-Correa et al., 2017, de Rham et 
al., 2007, Vendrame et al., 2017) and metabolic changes (Donnelly et al., 
2014). The previous chapter showed that IL-10 was capable of enhancing NK 
cell cytotoxicity but not cytokine secretion, highlighting the dichotomous 
activity of IL-10. The experiments in this chapter aim to understand whether 
IL-10 regulates the other mechanisms involved in NK cell activation.  
 
4.2 IL-10 does not mediate cellular changes associated with early 
activation 
Lymphocytes in culture grow as single cells in suspension. Activating signals 
induce conformational changes of integrins expressed on the cell surface, 
increasing the avidity of the receptors (Abram and Lowell, 2009) and causing 
the formation of cellular aggregates. To determine the effect of IL-10 on the 
ability of NK cells to form aggregates, isolated NK cells were cultured in the 
presence of IL-15, IL-10 or a combination of both for 48 hours and analysed 
by light microscopy. Stimulation of NK cells with IL-15 induced visible 
clumping of the NK cells and the formation of aggregates (Figure 14A, bottom 
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left panel); however, IL-10 stimulation of NK cells did not induce the formation 
of cellular aggregates (Figure 14A, top right panel). Those cells cultured with 
a combination of IL-15 and IL-10 show comparable morphology to those that 
have been cultured with IL-15 alone, suggesting that IL-10 does not inhibit the 
formation of these aggregates (Figure 14A, bottom right panel). 
 Additionally, lymphocyte activation can also be determined by 
measuring the cell surface expression of CD69, a well-established marker of 
lymphocyte activation (Cibrián and Sánchez-Madrid, 2017). PBMCs were 
stimulated as before with IL-15, IL-10 or a combination of both for 48 hours 
and analysed by flow cytometry. NK cells were gated based on lymphocyte 
size (FSC/SSC plots) and identified as CD56+ CD3neg as in Figure 7A. A small 
percentage of resting NK cells expressed CD69 (11%) and this varied greatly 
depending on the donor. Stimulation with IL-15 consistently upregulated 
expression of CD69 in the vast majority NK cells (88% in Figure 14B), whereas 
IL-10 stimulation did not increase CD69 expression (Figure 14B and C). 
Stimulation with the combination of IL-10 and IL-15 showed similar CD69 
expression to IL-15 stimulated NK cells (90%), indicating that IL-10 did not 
inhibit the expression of CD69. These measurements of early lymphocyte 





Figure 14: IL-10 does not induce NK cell activation markers 
(A) Isolated NK cells were cultured alone, with IL-10 (50 ng/mL), IL-15 (20 ng/mL) or 
both for 48 hours before being analysed by light microscopy. (B) PBMCs were 
cultured with IL-10 (50 ng/mL), IL-15 (20 ng/mL) or both for 48 hours prior to analysis 
of CD69 expression with flow cytometry. Graphs show percentage of NK cells 
positive for CD69 expression and (C) MFI (fold change from untreated), n=8. 

































































4.3 IL-10 does not upregulate expression of key NK cell activating 
receptors 
In addition to CD69, the complex NK cell receptor repertoire can be altered 
with activating stimuli. Cytokine stimulation plays a key role in augmenting NK 
cell receptor expression and upregulating activating receptors (Vendrame et 
al., 2017). To investigate whether IL-10 induced changes in NK cell receptor 
expression, PBMCs were stimulated with IL-15, IL-10 or a combination of both 
for 48 hours and analysed for the expression of the key activating receptors 
NKG2D, DNAM-1, NKp30 and NKp46. NKG2D and NKp46 were expressed 
on a high percentage of resting NK cells (85% and 86%, respectively) and the 
proportion of expressing cells remained unchanged in all conditions (Figure 
15A). However, IL-15 stimulation increased the expression of DNAM-1 and 
NKP30 as well as the density of NKG2D expression (Figure 15A and B). In 
contrast, treatment with IL-10 did not increase the expression of NKG2D, 
DNAM1, NKp30 or NKp46 (Figure 15A and B) and their expression on NK 
cells stimulated with a combination of IL-10 + IL-15 was similar to that of IL-
15 stimulated NK cells (Figure 15A and B). Multiple cellular populations within 
PBMCs express IL-10R and are capable of responding to IL-10. Stimulating 
PBMCs with IL-10 induces cellular interactions and the secretion of 
immunomodulatory molecules. Therefore, phenotyping NK cells from within 
this environment may not reveal how IL-10 affects NK cells, but rather the 
effects of these cellular interactions. To understand the direct effect of IL-10 
on NK cells, the above phenotyping assays were repeated in isolated NK cells. 
IL-10 did not significantly upregulate the expression of CD69, NKG2D, DNAM-
1, NKp30 or NKp46, inhibit IL-15 induced expression of receptors, or reduce 
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basal expression of any of the receptors investigated (Figure 16A-C). The 
exception to this is the density of NKp46 expression, which is significantly 
upregulated by IL-10 (P=<0.01). Additionally, a trend towards upregulation of 
NKG2D is also observed in IL-10 stimulated NK cells, but this does not reach 






Figure 15: IL-10 does not upregulate NK cell receptor expression (in 
PBMCs) 
PBMCs were cultured with IL-10 (50 ng/mL), IL-15 (20 ng/mL) or both for 48 hours 
prior to flow cytometry analysis for receptor expression. NK cells were identified as 
CD56+ and CD3neg, and the expression of the receptors on NK cells was measured. 
(A) Graphs show percentage of NK cells positive for receptor expression and (B) the 
MFI (fold change from untreated) for NKG2D (n=7), DNAM1 (n=3), NKp30 (n=3), and 












































































































































































































































































































































































































































































































































Figure 16: IL-10 does not upregulate NK cell receptor expression 
Isolated NK cells were cultured with 50 ng/mL IL-10, 20 ng/mL IL-15 or both for 48 hours, receptor expression was measured by flow cytometry. 
 (A) Example histograms from 1 donor, black = untreated, green = IL-10, red = IL-15 and blue = IL-10 + IL-15. (B) Graphs show percentage of NK cells 
positive for receptor expression and (C) MFI of receptor expression for CD69 (n=2), NKG2D (n=3), DNAM1 (n=3), NKp30 (n=2), and NKp46 (n=3). 
*P=<0.05, **P=<0.01, ***P=<0.001, ****P=<0.0001, ns = not significant  
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 4.4 IL-10 does not induce proliferation 
Resting NK cells are considered to be quiescent as they do not proliferate and 
display a gene signature that maintains the quiescent state (Dybkaer et al., 
2007). A variety of cytokines can induce the proliferation of NK cells, including 
common γ-chain cytokines IL-15 and IL-2, but also IL-12 and IL-18 (Wang et 
al., 1999, Carson et al., 1994, Lauwerys et al., 1999). Proliferation is 
characteristic of activated lymphocytes in inflammatory environments, 
therefore I investigated the effect of IL-10 on the proliferative properties of NK 
cells. Isolated NK cells were cultured in the presence of cytokines for 96 hours, 
DNA content and cell cycle stage was determined by flow cytometry using the 
fluorescent DNA intercalating agent, propidium Iodide (PI). A gating strategy 
to ensure only single cells were analysed was applied based on the cell height 
and area (Figure 17A). Untreated NK cells remained quiescent in G0/G1, 
indicated by a single peak of PI+ cells. IL-15 stimulation induced 28% of cells 
to enter S/G2 stage of the cell cycle, indicated by increased PI staining in a 
proportion of cells, identified in the S/G2 gate (Figure 17B and C). 
Interestingly, IL-10 stimulation did not induce cell cycle entry and all NK cells 
remained in the G0/G1 stage (Figure 17B and C), similar to resting NK. These 
data indicate that IL-10 does not provide a mitogenic signal to NK cells. I have 
previously shown that 50 ng/mL IL-10 was sufficient to induce phosphorylation 
of STAT3 and subsequently enhance cytotoxicity (Figure 7). It is possible 
however; that IL-10 is a much weaker activation signal than IL-15, and that 
increased concentrations of IL-10 could influence proliferation. To test this, IL-
10 and IL-15 were titrated onto NK cells and proliferation assessed as before. 
Low concentrations of IL-15 (0.2 – 2 ng/mL) did not induce cell cycle entry, 
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whereas the working concentration of 20 ng/mL and the higher concentration 
of 200 ng/mL induced similar percentages of cells to proliferate, 19.2% and 
22.06%, respectively. However, neither 50 ng/mL or a high concentration of 
500 ng/mL of IL-10 induced NK cell proliferation (Figure 17D). To determine if 
IL-10 has an inhibitory effect on proliferation, NK cells were stimulated with 
typical pro-proliferative cytokines: IL-15, IL-2, or IL-12 + IL-18 in the presence 
of 50 ng/mL IL-10. All cytokines induced NK cell proliferation which was 
neither enhanced or inhibited by IL-10 (Figure 17E).
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Figure 17: IL-10 does not drive proliferation 
(A) Isolated NK cells were cultured with 50 ng/mL IL-10, 20 ng/mL IL-15 or both for 
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cytometry. Flow cytometry gating strategy, events were collected on a linear scale 
and area vs. height was used to determine single cells. Single cells were then 
analysed further for PI fluorescence to determine DNA content/cell cycle stage. (B) 
Representative histograms of PI staining. S/G2 gating bar was set at 2% in the 
untreated control cells, cells in this gate are considered to be in S/G2 phase. (C) 
Percentage of cells that are in S/G2 phase (n=3), each shape represents a different 
donor (n=3). (D) Isolated NK cells were stimulated with increasing concentrations of 
IL-10 (0.5, 5, 50 and 500 ng/mL) or IL-15 (0.2, 2, 20 and 200 ng/mL) for 96 hours 
before being fixed in ethanol and stained with PI and analysed by flow cytometry 
(n=1). (E) Isolated NK cells were stimulated with either 10 ng/mL IL-15, 20 ng/mL IL-
2 or 10 ng/mL IL-12 + 100 ng/mL IL-18 with or without 50 ng/mL IL-10 (n=1). 
*P=<0.05; ns = not significant, determined using a repeated measures one-way 
ANOVA with Tukey’s multiple comparison test.
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4.5 IL-10 does not alter growth, but does increase protein synthesis 
Activation of cells is intrinsically linked to cellular changes such as increased 
protein production and cellular growth. As such, activated lymphocytes 
undergo metabolic reprogramming to facilitate these increased biosynthetic 
demands (Loftus and Finlay, 2016). These cellular changes are often co-
incident with proliferation, for example, proliferating cells must increase in size 
before division to produce daughter cells of the appropriate size. However, my 
current data suggests that IL-10 may activate NK cells in a different manner 
to IL-2 and IL-15, inducing increased killing capacity in the absence of 
proliferation. To further understand this, I determined the influence of IL-10 on 
protein content and cell size as a surrogate for increased metabolic activity of 
NK cells. In order to fulfil the increased demands of activation, activated NK 
cells increase the rate of protein synthesis. To measure protein synthesis, I 
used a puromycin incorporation assay. The structure of puromycin is similar 
to that of aminoacyl-transfer RNA, and as such can be incorporated into de 
novo proteins whilst in the elongation phase (Schmidt et al., 2009). Therefore, 
the incorporation of puromycin is used to detect newly synthesized proteins. 
To investigate whether IL-10 induces protein synthesis, I stimulated NK cells 
with IL-10 or IL-15 for 24 hours prior to adding puromycin into the culture. The 
cells were then lysed and analysed by western blotting for the presence of 
puromycin (using an anti-puromycin antibody). Protein synthesis was 
detected in all conditions, including the cells not treated with cytokine. 
Importantly, puromycin incorporation was blocked by the protein synthesis 
inhibitor cycloheximide (CHX). Increased protein synthesis was detected in 
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both IL-10 and IL-15 stimulated NK cells; however, IL-15 stimulation induced 
more protein synthesis (Figure 18A and B). This is unsurprising as previous 
data shows that IL-15 is a strong activator (Figures 9-17), inducing 
proliferation and upregulating the expression of activating receptors and IFN-
γ. These data indicate that IL-10 induces protein synthesis in NK cells, but not 
to the extent seen in IL-15 activated NK cells. 
To measure cell growth i.e. an increase in the physical size of a cell, I 
determined the FSC and SSC of NK cells by flow cytometry. These 
measurements provide a relative indication of size (FSC) and granularity 
(SSC) of cells. Isolated NK cells were stimulated for 48 hours with IL-10, IL-
15 or a combination before analysis by flow cytometry. Plotting the FSC and 
SSC values in histograms allows direct comparison of cytokine treated NK 
cells to untreated control cells. IL-15 stimulation induced an increase in both 
size and granularity of the NK cells, indicated by a shift of the histogram peaks 
to the right (Figure 19). IL-10 stimulation did not induce any measurable 
changes in size or granularity (Figure 19). Given the increased protein 
synthesis demonstrated in IL-10 treated NK cells, we might expect an increase 
in metabolic activity and therefore size. Again, similar to the proliferation data, 
the presence of IL-10 did not inhibit IL-15 induced growth (Figure 19).  
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Figure 18: Puromycin incorporation is increased by IL-10 stimulation 
(A) Isolated NK cells were stimulated with 50 ng/mL IL-10 or 20 ng/mL IL-15 for 24 
hours, 1 µg/mL puromycin was then added to the cultures and incubated for 10 mins. 
CHX (30 µg/mL) was used as a negative control for the assay; added into IL-15 
stimulated NK cells to inhibit protein synthesis. Cells were then lysed and analysed 
by western blotting for puromycin expression (n=1). (B) Quantification of the western 
blot using β-actin as a loading control, performed using ImageJ software (n=1).
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Figure 19: IL-10 does not induce NK cell growth 
Isolated NK cells were cultured with 50 ng/mL IL-10, 20 ng/mL IL-15 or both for 48 
hours prior to being analysed by flow cytometry. Images show contour plots, SSC 
histograms and FSC histograms of NK cells (green). Grey peaks in histograms 
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4.6 IL-10 does not increase glucose uptake 
Increased metabolic activity is essential to facilitate cell growth and 
proliferation of activated lymphocytes. Quiescent lymphocytes use glycolysis 
and OXPHOS to maintain homeostatic levels of ATP, whereas activated 
lymphocytes increase the glycolytic flux (rate of glycolysis). This increase is a 
very inefficient way to generate ATP and much of the pyruvate is converted 
into lactate and excreted from the cell, however, it enables the metabolic 
intermediates to be diverted into biosynthetic pathways to generate material 
such as nucleotides and lipids to support growth and proliferation (Figure 20A) 
(Loftus and Finlay, 2016). This altered metabolism is known as aerobic 
glycolysis (the Warburg effect) and can be measured by an increased uptake 
of glucose. Increased glucose uptake is indicative of the increased glycolytic 
flux which is characteristic of this metabolic shift. To confirm that IL-10 treated 
NK cells do not have increased metabolic activity as indicated by cell growth 
measurements, I have used a glycolytic flux measurement as a surrogate for 
cellular metabolism. In order to investigate how the metabolism of cytokine 
stimulated NK cells differed from untreated NK cells, I used a fluorescent 
glucose analogue, 2-deoxyglucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl) amino]-2-deoxyglucose (2-NBDG), to determine glucose uptake 
in NK cells. NK cells were cultured for 48 hours in the presence of IL-10 or IL-
15, the media was then removed and replaced with glucose-free media and 
2-NBDG (section 2.5). Cells that had not been incubated with 2-NBDG were 
used as a negative control (grey peaks). All conditions including the untreated 
control displayed bimodal peaks for 2-NBDG fluorescence, which suggests 
there could be populations with differing metabolic activity. IL-15 stimulation 
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resulted in increased glucose uptake in both populations (red peak), whilst IL-
10 stimulated NK cells (green peak) showed similar glucose uptake to 
untreated NK cells (black peak). Unexpectedly, cells stimulated with both IL-
10 and IL-15 exhibited slightly increased glucose uptake (blue peak) in 
comparison to IL-15, suggesting IL-10 may enhance IL-15 induced glucose 
uptake (Figure 20B). As with each of the other IL-15 induced activation 
mechanisms discussed, IL-10 does not inhibit glucose uptake. These data 
indicate that IL-10 mediated NK cell cytotoxicity may have different metabolic 
requirements to IL-15 activation, and is independent of cell growth. These data 
should be interpreted with caution as recent data suggests that 2-NBDG may 
not be a reliable reporter of glucose uptake (discussed in section 4.7).  
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Figure 20: Glucose fluxing is not enhanced by IL-10 
 (A) Schematic diagrams of glycolysis and aerobic glycolysis (Loftus and Finlay, 
2016). (B) Isolated NK cells were stimulated with 50 ng/mL IL-10, 20 ng/mL IL-15 or 
both for 48 hours; cells were placed in glucose free media for 1 hour before adding 
the glucose analogue 2-NBDG and then analysed by flow cytometry. Grey peak = 
NK cells without 2-NBDG, black = untreated NK cells, green = IL-10 stimulated NK 
cells, red = IL-15 stimulated NK cells, blue = IL-10 + IL-15 stimulated NK cells. D1 = 
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4.7 IL-10 does not induce mTOR signalling 
I have shown that IL-10 does not provide a growth/proliferation signal to NK 
cells, however, it does increase protein content and appears to enhance IL-
15 induced glucose uptake (Figure 18A and B, Figure 20B). To further 
investigate the effects of IL-10 on metabolism, I investigated the expression 
of a key metabolic regulator, mammalian target of rapamycin (mTOR). Recent 
studies have identified mTOR as a key regulator of the metabolic shift in 
activated lymphocytes, and it is reported to be activated in NK cells by IL-2, 
IL-12, IL-15 and IL-18 (Marçais et al., 2014, Donnelly et al., 2014). 
Considering that IL-10 did not increase mechanisms reported to be 
downstream of mTOR activation such as cell growth or proliferation, it is 
unlikely that IL-10 induces mTOR activation. To confirm this hypothesis, I 
investigated the phosphorylation of proteins in the mTOR pathway in 
response to IL-10 stimulation, specifically phospho-AktT308 (p-Akt) and 
phospho-S6S240/244 (p-S6). Isolated NK cells were stimulated with IL-10 or IL-
15 for 45 minutes before analysis by intracellular flow cytometry for p-Akt 
expression (Figure 21 A and B), or 48 hours before western blotting to 
determine p-S6 expression (Figure 21C). As expected, IL-15 stimulation 
induced the phosphorylation of both Akt and S6, indicating that IL-15 activates 
the mTOR pathway as previously described (Marçais et al., 2014). Stimulation 
with IL-10 did not increase expression of p-Akt or p-S6 and therefore did not 
activate the mTOR pathway, correlating with the lack of cell growth and 
proliferation. 
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Figure 21: IL-10 does not induce phosphorylation of Akt or S6 
Isolated NK cells were stimulated with 50 ng/mL IL-10 or 20 ng/mL IL-15 for 45 
minutes before being analysed by intracellular flow cytometry. (A) NK cells were 
gated on based on FSC and SSC and further selected for live cells based on negative 
staining with a dead cell discriminator (Zombie NIR™). (B) Intracellular staining using 
an anti-p-Akt antibody, positive staining was determined by use of an isotype control 
antibody and setting the gate at 2% positive (black vertical line) (n=1). (C) NK cells 
were stimulated with 50 ng/mL IL-10 or 20 ng/mL IL-15 for 48 hours before being 
lysed and analysed by western blotting for phosphorylated S6 expression (pS6);  
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4.8 Discussion  
The activation of lymphocytes is an overarching phenomenon that 
encompasses many cellular changes. Metabolic reprogramming of cells has 
been identified as a key step that facilitates many of these processes, enabling 
cells to cope with the demands of rapid proliferation and synthesis of 
immunomodulatory molecules (Donnelly et al., 2014). In this chapter, I have 
investigated cellular changes associated with activation in isolation to try to 
understand the unique effects of IL-10 on NK cells. IL-15 is a potent NK cell 
activator and induces changes to each of the activation mechanisms 
investigated: cytotoxicity, cytokine production, activating receptor expression 
and proliferation. Conversely, I have shown that IL-10 upregulates cytotoxicity 
independently of other activating mechanisms, suggesting that IL-10 
regulates independent/divergent pathways that induce only some of the 
cellular changes associated with activation. Moreover, IL-10 mediated 
cytotoxicity was independent of the enhanced metabolic requirements of IL-
15 mediated activation. Indeed, the mTOR pathway was not activated in 
response to IL-10, leading to the proposed mTOR independent activation of 
NK cells.  
 As previously discussed, the expression of NK activating receptors is 
a key determinant in cellular responses. Many studies have previously shown 
that the expression of both activating and inhibitory receptors can be altered 
by cytokine stimulation (Vendrame et al., 2017, de Rham et al., 2007, Wilson 
et al., 2011). Despite enhancing cytotoxicity, IL-10 does not significantly alter 
the expression of key activating NK cell receptors NKG2D, NKp30, or DNAM1. 
This was surprisingly given that previous studies have shown NKG2D 
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expression to be transcriptionally controlled in a STAT3 dependent manner 
(Zhu et al., 2014). This study detailed that upon stimulation with 50 ng/mL IL-
10, NKG2D expression was upregulated 1.6-fold and peaked at 48 hours post 
treatment. In contrast to this, the data presented in this study does not show 
enhanced NKG2D with IL-10 stimulation. Interestingly, a trend towards 
upregulation of NKG2D and significant upregulation of NKp46 was observed 
when isolated NK cells were stimulated with IL-10 (1.3-fold and 1.4-fold, 
respectively). To gain a better understanding of how IL-10 alters NKR 
expression, further experiments to increase the number of donors would be 
needed to perform accurate statistical analysis.  
 The CD69 molecule is not, to the best of our knowledge, involved in 
target cell recognition. However, it is rapidly upregulated on activated 
lymphocytes and is commonly used as a marker of activation. The exact 
function of CD69 has not been fully elucidated, but a role for CD69 in the 
migration and metabolism of lymphocytes has been identified through protein-
protein interactions with sphingosine-1-phosphate receptor 1 (S1P1) and the 
amino-acid transporter complex (LAT-1/CD98), respectively (Cibrián and 
Sánchez-Madrid, 2017). Immune surveillance requires the continuous 
circulation of lymphocytes through lymphoid organs and egress of 
lymphocytes from lymph nodes (LN) is mediated by gradients of the 
chemoattractant sphingosine 1-phosphate (S1P). High concentrations in the 
blood/lymph, secreted by endothelial cells, and low concentrations in the 
lymph nodes direct the migration of lymphocytes through binding of S1P-
receptors (S1PRs) (Rivera et al., 2008). These interactions can be transiently 
disrupted by upregulation of CD69 in activated lymphocytes. CD69 forms 
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lateral protein-protein complexes with S1PR, resulting in the downmodulation 
of S1PRs and the retention of lymphocytes in the LN (Shiow et al., 2006). 
Similarly, CD69 has also been shown to interact with LAT-1/CD98 on 
activated T cells. This interaction has been reported to stabilize the cell 
surface expression of LAT-1/CD98, thereby enhancing amino-acid uptake 
enabling greater signalling through mTOR (Cibrián and Sánchez-Madrid, 
2017). In this study, CD69 was not upregulated in response to IL-10, which is 
perhaps unsurprising. Activated NK cells producing IFN-γ migrate to lymph 
nodes and aid cytotoxic T cell priming (Martín-Fontecha et al., 2004). The data 
presented in Chapter 3 demonstrated that IL-10 does not induce IFN-γ 
production from NK cells, therefore retaining IL-10 activated NK cells in the 
LN would not be useful. Furthermore, as IL-10 stimulated NK cells did not 
induce mTOR activity, increased LAT-1/CD98 activity would not be beneficial.  
 Many studies report differential roles of IL-10 in proliferation, which 
differ between cell types, combinations of cytokines and the activation status 
of cells. For instance, in intestinal T cell populations, the nature of the stimulus 
was observed to be the defining factor in whether IL-10 was anti- or pro-
proliferative. IL-10 inhibited the proliferation of phytohaemagglutinin (PHA) 
activated T cells, but enhanced the proliferation of IL-2 activated T cells (Ebert, 
2000). Similarly, Groux et al. observed that IL-10 acted as a co-factor with IL-
2 to enhance CD8 T cell proliferation, but was unable to induce T cell 
proliferation in isolation. Moreover, IL-10 inhibited proliferation when T cells 
were stimulated with APCs, but not via CD3 activation, suggesting that the 
inhibition was indirect and due to the inhibition of APC function (Groux et al., 
1998). Using a murine macrophage model, IL-10 was revealed to inhibit 
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proliferation by arresting cells in G1, and that inhibition was not due to IL-10 
induced secretion of auto/paracrine anti-inflammatory mediators (O'Farrell et 
al., 1998). Supporting this, gene profile analysis performed in IL-10 stimulated 
NK cells identified multiple upregulated genes associated with cell-cycle-
suppression such as P21 and RB (Mocellin et al., 2004). p21 and pRb both 
play a role in regulating cell-cycle progression. p21 is a cyclin-dependent 
kinase (CDK) inhibitor that prevents cell cycle progression at multiple points 
by binding to cyclin/CDK complexes (D/CDK4/6 in G1 phase, cyclin E/CDK2 
at G1/S phase and A/CDK1,2 through S phase) (Karimian et al., 2016) 
whereas pRb inhibits cell cycle progression at the ‘restriction point’ in G1 
phase of the cell cycle. Hypophosphorylated pRb prevents the transcription of 
genes necessary for progression into S phase by binding E2F transcription 
factors. Mitogenic signals are required to inactivate pRb, which requires 
hyperphosphorylation mediated by cyclin/CDK complexes (Giacinti and 
Giordano, 2006).  
In contrast to IL-10 acting in a supporting role, IL-10 has been shown 
to induce proliferation to a greater extent than both IL-18 and IL-12 in bone-
marrow-derived murine NK cells, and displays selective additive proliferative 
effects in combination with IL-18, but not IL-12 (Cai et al., 1999). The data 
regarding the effect of IL-10 on proliferation is somewhat contradictory and it 
appears that IL-10 can play dual roles. Here, I attempted to uncover how IL-
10 affected the proliferation of human primary NK cells, in isolation and in 
combination with other activating cytokines. IL-10 alone did not induce 
proliferation of NK cells at any concentration used (5-500 ng/mL), or enhance 
the proliferative effects of IL-15 or IL-12/IL-18, and only a modest increase 
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was observed in combination with IL-2 (n=1). Additionally, IL-10 did not inhibit 
the proliferative effects of IL-15, IL-2 or IL-12/IL-18.  
 In addition to proliferation, IL-10 did not induce cell growth but did 
increase protein synthesis. Preliminary data suggests that protein synthesis 
was modestly increased in comparison to the increase observed with IL-15, 
reflective of the number of cellular changes IL-15 has been shown to induce. 
To support these cellular changes, IL-15 signals for a metabolic switch, 
enabling activated lymphocytes to fulfil energetic demands. In line with other 
studies, this is demonstrated by increased glucose uptake and mTOR 
activation. Using an in vivo model, poly I:C activated NK cells were found to 
be larger, have a higher level of glucose fluxing, and increased expression of 
nutrient transporters in comparison to untreated NK cells, all of which were 
impaired in the presence of the mTOR inhibitor, rapamycin. Additionally, ex-
vivo stimulation of NK cells with IL-2/IL-12 upregulated levels of glycolysis and 
OXPHOS, however, only glycolysis was mTOR-dependent (Donnelly et al., 
2014). Similarly, Marçias et al. also observed mTOR dependent cell growth, 
increased aerobic glycolysis and increased OXPHOS of NK cells in response 
to IL-15. mTOR deficient murine NK cells had reduced expression of IL-15R 
and dramatically reduced proliferation during development stages. 
Additionally, mTOR deficient NK cells exhibited impaired growth and glucose 
uptake when challenged with poly I:C. Interestingly, this study also observed 
that poly I:C stimulation of mTOR deficient cells had reduced granzyme B 
expression, but IFN-γ production was unaffected in comparison to WT cells 
(Marçais et al., 2014). I have shown that IL-10 does not induce mTOR 
signalling and consequently does not increase proliferation. Moreover, this 
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finding supports a rationale for the lack of IFN-γ production by IL-10 
stimulation that is consistent with current literature (Mah and Cooper, 2016, 
Keppel et al., 2015, Keating et al., 2016, Donnelly et al., 2014).  Although 
preliminary data in Figure 20 suggest that IL-10 does not impact glucose 
uptake in NK cells, this must be interpreted with caution. In a recent study, 
Sinclair et al. observed that 2-NBDG uptake correlated well with relative 
glucose transporter expression and metabolically active CD8+ T cells; 
however, 2-NBDG uptake was also observed in non-metabolically active 
CD4+/CD8+ double positive thymocytes. Through interrogation of proteomic 
data sets, it was shown that murine T cells did not express several glucose 
transporters and co-transporters, including Glut 2 (a validated target of 2-
NBDG), and that 2-NBDG did not follow simple glucose transporter principles 
as uptake was not blocked by inhibition of glucose transporters or 
competitively inhibited by substrates. These data indicate that 2-NBDG uptake 
alone may not be a reliable reporter of glucose uptake or glycolytic activity. 
(Sinclair et al., 2020). 
 These data show that IL-10 stimulated NK cells do not undergo the 
same process of cell growth and proliferation that IL-15 treated cells do, and 
therefore do not need to undertake the same levels of biosynthetic activity 
associated with IL-15 treatment. However, IL-10 did induce JAK/STAT 
signalling, upregulate granzyme B expression and enhance cytotoxicity 
(Chapter 3). The ability to induce some mechanisms of activation and not 
others suggests that each of these mechanisms are governed by independent 
signalling pathways. Investigations in the next chapter will focus on identifying 
key pathways required for IL-10 induced activation of NK cells.  
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Chapter 5 
Distinct modes of NK cell activation by IL-10 and IL-15 
5.1 Introduction 
Previous chapters highlighted the diversity of IL-15 and IL-10 induced NK cell 
activation, the former utilising multiple mechanisms to induce robust 
activation, and the latter selectively enhancing just a fraction of these 
mechanisms. It is well-known that STAT3 plays a key role in IL-10 signalling 
(Verma et al., 2016, O'Farrell et al., 1998, Niemand et al., 2003), and 
activation of this pathway has been confirmed in primary human NK cells 
(Figure 8). Experiments performed in this chapter aimed to further understand 
how STAT3 signalling determines NK cell activity and which, if any, other 
pathways are involved. Using a combination of selective and non-selective 
inhibitors, this chapter investigates the STAT3-dependancy of IL-10 mediated 
cytotoxicity.  
 
5.2 IL-10 induced activation differs from IL-15 induced activation 
IL-10 mediates only a fraction of NK cell functions compared to IL-15. One 
possibility is that IL-10 is simply a weak NK cell stimulus compared to IL-15.  
I previously demonstrated that IL-15 induced NK cell proliferation at 
concentrations as low as 10 ng/mL, whilst IL-10 did not induce proliferation at 
low or high concentrations (0.5-500 ng/mL) (Figure 18). To further investigate 
the ‘strength’ of IL-10 compared to IL-15 stimulation, I analysed the surface 
expression of CD69 and intracellular granzyme B, proteins that I have 
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previously shown to be unaffected and upregulated by IL-10 stimulation, 
respectively (Figures 8, 13B and C).  
NK cells were stimulated with increasing concentrations of IL-10 (0.5, 5, 50 
and 500 ng/mL) or IL-15 (0.2, 2, 20 and 200 ng/mL) for 48 hours before being 
analysed by flow cytometry. As expected, the majority (>97%) of untreated 
NK cells were positive for granzyme B expression (Figure 22A); therefore, 
changes in MFI were used to measure changes in expression. In agreement 
with the previous data (Figure 9), both IL-15 and IL-10 upregulated the 
expression of granzyme B. Granzyme B expression in IL-15 stimulated cells 
peaked at 20 ng/mL (2.1-fold-increase), whereas the highest concentration of 
IL-10 (500 ng/mL) resulted in the highest expression of granzyme B, 1.5-fold-
increase compared to 1.3-fold-inrease with 50 ng/mL (Figure 22B).  
IL-15 induced CD69 expression at all concentrations; however, IL-10 did not 
induce CD69 expression even at the highest concentration of 500 ng/mL 
(Figure 22C). This selective upregulation of granzyme B but not CD69 
suggests that IL-10 is not weakly activating the same pathways as IL-15, but 
rather activating a subset of, or different pathways to achieve NK cell 
activation.  
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Figure 22: High concentration of IL-10 does not induce CD69, but does 
increase granzyme B 
 (A) NK cells were cultured with increasing concentrations of IL-10 (0.5, 5, 50 and 
500 ng/mL) or IL-15 (0.2, 2, 20 and 200 ng/mL) for 48 hours prior to being analysed 
by flow cytometry for cell surface expression of CD69 (n=1) and (B) intracellular 
expression of granzyme B (n=1). (C) Histograms of CD69 expression, positive gating 
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5.3 IL-10 induced NK activation is susceptible to inhibition by TGF-β 
IL-15 stimulates robust activation of NK cells through the activation of multiple 
pathways, resulting in enhanced cytotoxicity, receptor expression, cytokine 
production and proliferation (Figures 9-17) (Wilson et al., 2011, Carson et al., 
1994, Gosselin et al., 1999). A key component of this activation is the 
increased metabolic capacity that is orchestrated via the mTOR pathway, 
shown to be required for optimum NK cell activation (Marçais et al., 2014, 
Donnelly et al., 2014, Keating et al., 2016). TGF-β, a potent inhibitor of IL-15 
stimulation, has been shown to inhibit IL-15 induced NK cell activity via mTOR 
inhibition (Viel et al., 2016). I have previously shown that IL-10 does not induce 
mTOR signalling in NK cells, I therefore hypothesised that IL-10 stimulated 
NK cells would be refractory to TGF-β inhibition; such activity might have 
important implications for immunotherapy.  To test this hypothesis, NK cells 
were cultured with IL-10 or IL-15 +/- TGF-β for 48 hours prior to analysing 
cytotoxicity and degranulation (as described previously in chapter 2, 3). As 
expected, TGF-β inhibited IL-15 induced NK cell-mediated killing of K562 cells 
at both E:T ratios tested and, contrary to my hypothesis, TGF-β also inhibited 
the cytotoxicity of IL-10 activated NK cells (Figure 23A and B).  Similar results 
were obtained when assaying NK cell degranulation in response to K562 and 
SKOV3 target cells (Figure 23C). In the presence of TGF-β, target cell death 
was reduced by 34% at E:T 1:1 and 69.5% at E:T 5:1 (Figure 23A and B). 
Degranulation was also reduced by 31.1% against K562 and 58.8% against 
SKOV3 (n=1) (Figure 23C). These preliminary data indicate that TGF-β is 
inhibiting IL-10 independently of its effects on mTOR (as mTOR is not 
activated by IL-10; Figure 21). Therefore, I investigated whether TGF-β 
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inhibited the STAT3 signalling pathway. Isolated NK cells were cultured with 
IL-10 +/- TGF-β for 48 hours before being lysed and analysed by western 
blotting for expression of pSTAT3Y705. Surprisingly, TGF-β did not inhibit IL-
10 induced STAT3Y705 phosphorylation; however, granzyme B expression 
was reduced to basal levels in the presence of TGF-β (Figure 23D). This 
suggests that TGF-β inhibits IL-10 induced NK cell activation independently 
of mTOR and STAT3 phosphorylation, and that IL-10 is potentially stimulating 
additional pathways to induce NK cell activation.  
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Figure 23: TGF-β inhibits IL-10 induced NK cell cytotoxicity 
NK cells were treated for 48 hours with 50 ng/mL IL-10 or 20 ng/mL +/- 5 ng/mL TGF-
β. NK cells were then co-cultured with CTV labelled K562 target cells at 1:1 (n=4) 
and (B) 5:1 (n=3) E:T, dead cells were identified using Zombie NIR™. (A) Graphs 
show mean target cell death at 1:1 (n=4) and (B) 5:1 (n=3) and were analysed using 
repeated measures one-way ANOVA with Tukey’s multiple comparison test. (C) NK 
cells were treated and co-cultured with CTV labelled K562 target cells (as above) 
prior to being analysed by flow cytometry for CD107a expression. Graph shows mean 
expression from triplicates (n=1). (D) NK cells were stimulated with 50 ng/mL IL-10 
+/- 5 ng/mL TGF-β for 48 hours prior to being lysed and analysed by western blotting 
(n=1). ns = not significant.  
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5.4 Potential pathways activated by IL-10 
The Jak1/STAT3 pathway is considered to be the central mediator of IL-10 
function; however, activation of others pathways such as PI3K has also been 
reported in monocytes and promyeloid cells (Verma et al., 2016, Zhou et al., 
2001, Crawley et al., 1996). In order to investigate whether other signalling 
pathways were activated in NK cells, the phosphorylation of key immune 
signalling proteins was investigated. Isolated NK cells were either 
unstimulated, or stimulated with IL-10 for 30 minutes prior to being lysed and 
analysed using a membrane-based sandwich immunoassay (Figure 24A) 
(see section 2.8). Despite previously showing highly increased pSTAT3Y705 
levels through conventional western blotting methods (Chapter 3 Figure 8), 
the phospho-kinase array revealed only modest upregulation with IL-10 
stimulation (~1.4-fold increase) (Figure 24C). In fact, all proteins showed only 
small changes in their phosphorylation levels with IL-10 stimulation compared 
to untreated NK cells, with the highest increase seen in pSTAT5bY699. STAT5 
is not reported to be IL-10 activated (Lai et al., 1996), some studies show that 
IL-10 signalling is able to induce the dimerisation of STAT3/STAT5 
complexes, but this has only been shown in a cell restricted manner (Weber-
Nordt et al., 1996, Jens et al., 1996). This results from this assay are 
inconclusive, therefore, further investigation into IL-10 activated signalling 
pathways in NK cells is required.  
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Figure 24: Proteome Profiler 
(A) Isolated NK cells were either untreated or stimulated with 50 ng/mL IL-10 for 30 
minutes, cell lysates were subsequently washed over the phospho-kinase array 
membranes. (B) ImageJ plugin protein array analyser was used to analyse the blots. 
Red circles define area to be measured. BG = Background, green boxes are 
membrane alignment dots, blue boxes are negative controls. (C) Phospho-protein 
expression is displayed as fold change from the corresponding protein in the 
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5.5 STAT3 phosphorylation is required for IL-10 mediated cytotoxicity  
As previously shown, TGF-β did not inhibit phosphorylation of STAT3 but did 
inhibit granzyme B upregulation (Figure 23D). To further investigate the 
mechanisms by which STAT3 mediates NK cell activation, I evaluated the 
effects of STAT3 inhibition on IL-10 induced NK cell cytotoxicity using 
granzyme B expression and cytotoxic activity as readouts. To inhibit STAT3 
mediated signalling, a small-molecule inhibitor of STAT3 was used; c188-9. 
This inhibitor blocks ligand-induced STAT3 phosphorylation and dimerisation 
by targeting the phosphotyrosine peptide binding site within the SH2 domain 
(Redell et al., 2011). NK cells were stimulated with IL-10 in the presence of 
c188-9 for 48 hours before analysing the expression of granzyme B, or being 
co-cultured with K562 target cells and analysing target cell death. Increasing 
concentrations of c188-9 (1 μM, 5 μM and 10 μM) reduced the expression of 
pSTAT3 in a dose-dependent manner whilst the expression of total STAT3 
remained constant, confirming the specificity of phosphorylation inhibition. In 
the presence of c188-9, granzyme B expression was also reduced in a dose-
dependent manner (Figure 25A), confirming a role for STAT3 in the IL-10 
mediated regulation of granzyme B.  
Furthermore, preliminary results from NK cell: target cell co-cultures also show 
that, in the presence of c188-9, target cell death was reduced in a dose-
dependent manner (Figure 25B). This finding further supports a role of STAT3 
signalling in IL-10 mediated NK cell cytotoxicity.  
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Figure 25: STAT3 inhibition reduces granzyme B and target cell death 
(A) NK cells were stimulated with 50 ng/mL IL-10 + increasing concentrations of 
C188-9 (1, 5, 10 μM) for 48 hours prior to being lysed and analysed by western 
blotting (also see Figure 23D) (STAT3 was used as a loading control and to confirm 
phosphorylation inhibition) (n=1), or (B) co-culturing with CTV labelled K562 target 
cells at 5:1 E: T. Target cell death was measured using Zombie NIR™. Graphs shows 
mean target cell death from triplicates (n=1). 
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5.6 IL-21 and IL-10 activate NK cells in a similar fashion 
To explore the role of STAT3 in NK cell activation further, I employed another 
STAT3 activating cytokine, IL-21. I investigated pathways that I have 
previously shown to be regulated by IL-10 treatment (granzyme B expression, 
cytotoxicity and degranulation). Treatment with IL-21 alone, or in combination 
with other cytokines, has been shown to activate NK cells via STAT3 (Li et al., 
2015, Skak et al., 2008, de Rham et al., 2007, Eriksen et al., 2009, Strengell 
et al., 2003) and enhance cytotoxicity (Bhatt et al., 2015). Therefore, I 
hypothesised that IL-10 and IL-21 would induced the same degree of 
activation in NK cells.  Firstly, to confirm that IL-21 signalled via STAT3, NK 
cells were stimulated with 50 ng/mL IL-21 and the expression of 
phosphorylated STAT3 was determined by western blot analysis (Figure 26A). 
The results show that IL-21 induced STAT3 phosphorylation to a lesser extent 
than IL-10, but in combination with IL-15, phosphorylation of pSTAT3 
expression was comparable to IL-10 stimulation. Granzyme B expression was 
upregulated in response to both IL-21 and IL-10 to a similar degree, but to a 
lower extent than IL-15 (Figure 26A). Unlike IL-10, these results do not show 
an additive effect of IL-21 in combination with IL-15; however, this is only from 
one donor and further investigations are required to confirm this. Similar to the 
previous observation in IL-10 stimulated NK cells (Figure 26A), the presence 
of TGF-β did not inhibit IL-21 induced STAT3 phosphorylation, but did reduce 
the expression of granzyme B (Figure 26A).  
To investigate the effect of IL-21 on cytotoxicity, isolated NK cells were 
stimulated with IL-10, IL-15 or IL-21 for 48 hours prior to being co-cultured 
with K562 target cells. Target cell death and NK cell degranulation was then 
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analysed using flow cytometry (as detailed in Figures 10 and 11). IL-21 
showed similar activity to IL-10, increasing degranulation and target cell 
death. Compared to the untreated control, IL-21 increased target cell death 
by 1.87-fold (Figure 26B) and degranulation by 1.26-fold, whilst IL-10 
increased target cell death and degranulation by 1.5-fold and 1.23-fold, 
respectively (Figure 26C). Similar to previous results, IL-15 induced higher 
levels of degranulation and target cell death than IL-21 or IL-10, indicating that 
these cytokines are less potent activators of NK cells. To further compare the 
similarities of IL-21 and IL-10, I evaluated the expression of CD69, as previous 
results show that this is not regulated by IL-10 stimulation, hence it is unlikely 
to be downstream of STAT3. NK cells were stimulated with IL-21, IL-10 or IL-
15 for 48 hours prior to be analysed by flow cytometry for surface expression 
of CD69. These results show that the expression of CD69 remained 
unchanged in IL-21 stimulated NK cells (Figure 26D). Taken together, these 
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Figure 26: IL-21 induces NK cell cytotoxicity 
(A) NK cells were stimulated with combinations of 50 ng/mL IL-10, 20 ng/mL IL-15, 
50 ng/mL IL-21 and 5 ng/mL TGF-β for 48 hours prior to being lysed and analysed 
by western blotting (n=1). (B) NK cells were treated for 48 hours with 50 ng/mL IL-
10, 20 ng/mL IL-15 or 50 ng/mL IL-21prior to being co-cultured with CTV labelled 
K562 target cells at 5:1 E:T, dead cells were identified using Zombie NIR™. Graphs 
shows mean target cell death (n=2). (C) NK cells were treated and co-cultured with 
CTV labelled K562 target cells (as above), CD107a expression was analysed by flow 
cytometry (n=2). (D) NK cells were treated for 48 hours with 50 ng/mL IL-10, 20 ng/mL 
IL-15 or 50 ng/mL IL-21, prior to being analysed by flow cytometry for CD69 
expression (n=1).  
A
CB
IL-10 - + - - - -
IL-21 - - + + + -
IL-15 - - - + - +
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5.7 NK cell cytotoxicity is independent of proliferation 
It is unclear whether STAT3 is the sole pathway that mediates IL-10 activation 
of NK cells, but efforts to identify further pathways (such as the use of the 
phosphoproteome screen in Figure 24) were inconclusive.  
The data presented here show that IL-10 induces NK cell cytotoxicity 
independently of other mechanisms, such as proliferation. In contrast, IL-15 
stimulates both proliferation and cytotoxicity very strongly. I therefore 
investigated the contribution of NK cell proliferation to cytotoxicity by 
specifically inhibiting cell cycle progression. To do this, isolated NK cells were 
cultured with IL-15 +/- palbociclib, a CDK4/6 inhibitor that stalls cells in the 
G1/S phase; these NK cells were then assayed for their cytotoxicity activity 
(as previously described in section 2.3). To confirm that palbociclib inhibited 
proliferation in NK cells, palbociclib was added into cytokine stimulated cell 
cultures for 96 hours prior to analysing the DNA content and cell cycle stage 
with PI staining (as previously described in section 2.6). As expected, IL-15 
induced NK cell proliferation (44% of cells in G2/S phases) and this was 
completely inhibited in presence of palbociclib (3% of cells in G2/S phases) 
(Figure 27A). As found in previous cytotoxicity assays, using either IL-15 or 
IL-10 stimulated NK cells resulted in more target cell death compared to 
untreated NK cells (Figure 27B). As expected, palbociclib did not inhibit IL-10 
induced cytotoxicity (E:T 1:1 13.2% vs 12.89%; E:T 5:1 43.2% vs 39.7% for 
IL-10 and IL-10 + palbociclib, respectively). Interestingly, despite profoundly 
inhibiting proliferation, the presence of palbociclib did not inhibit the 
cytotoxicity of IL-15 stimulated NK cells (E:T 1:1 20.5% vs 19.4%; E:T 5:1 
65.8% vs 56.5% for IL-15 and IL-15 + palbociclib, respectively) (Figure 27B). 
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This suggests that IL-15 induced proliferation and cytotoxicity are governed 
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Figure 27: Proliferation is not essential for IL-15 induced cytotoxicity 
(A) Isolated NK cells were cultured with 20 ng/mL IL-15 +/- 1 μM palbociclib for 96 
hours before being analysed for cell cycle phase using PI staining and flow cytometry. 
Flow cytometry gating strategy; events were collected on a linear scale and area vs. 
height was used to determine single cells. Single cells were then analysed further for 
PI fluorescence. Histograms of PI staining; S/G2 gating bar was set at 2% in the 
untreated control cells, cells in this gate are considered to be in S/G2 phase 
(representative of n=3). (B) NK cells were treated for 48 hours with 50 ng/mL IL-10 
or 20 ng/mL IL-15 +/- 1 μM palbociclib. NK cells were then co-cultured with CTV 
labelled K562 target cells at 1:1 and 5:1 E:T; dead cells were identified with  Zombie 
NIR™ using flow cytometry. Graphs shows mean target cell death (n=3); ns = not 
significant, determined using a repeated measures one-way ANOVA with Tukey’s 
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5.8 Discussion 
Previous chapters have highlighted several differences between IL-15 and IL-
10 induced NK cell activation. In this chapter, I aimed to further understand 
these differences by investigating the STAT3 dependency of IL-10 induced 
activation. NK cells are activated by several different cytokines, each of which 
induce unique combinations of cytokine secretion, protein synthesis and 
cytotoxicity (Lauwerys et al., 2000, Fehniger et al., 1999, Nguyen et al., 2002, 
Meghnem et al., 2017, Wang et al., 2014, Ferlazzo et al., 2004). Furthermore, 
combinations of cytokines can act synergistically to enhance NK cells activity 
(Strengell et al., 2003, Lauwerys et al., 1999). Experiments performed in this 
chapter confirm that IL-10 activation is not a weaker form of IL-15 activation 
but is in fact distinct from IL-15 activation. Several cytokines preferentially 
enhance specific activatory mechanisms; for instance, IL-12 and IL-18 
enhance IFN-γ expression to  greater extent than IL-15 (Fehniger et al., 1999) 
and IL-15 induces greater proliferation than IL-12 (Nguyen et al., 2002). Even 
IL-2 and IL-15, cytokines that share receptor components, have numerous 
differences in their downstream effects. Wang et al. identified 374 differentially 
expressed genes that resulted in enhanced proliferation capacity of IL-15 
stimulated NK cells and greater cytotoxic potential of IL-2 stimulated NK cells 
(Wang et al., 2014). Here I have shown that IL-10 activates only a subset of 
activatory mechanisms in comparison to IL-15 stimulated NK cells. 
Concentrations as high as 500 ng/mL of IL-10 were not capable of inducing 
CD69 expression or proliferation, both of which are hallmarks of IL-15 
activation. However, higher granzyme B expression was induced with 500 
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ng/mL than 50 ng/mL IL-10, highlighting the ability of IL-10 to further enhance 
the cytotoxicity potential but, not proliferation. 
As previously shown, IL-10 does not activate the mTOR pathway in NK 
cells (Figure 21), therefore it was surprising to find that IL-10 induced 
activation was susceptible to inhibition by TGF-β. It has long been known that 
TGF-β is a potent inhibitor of NK cell functions. Reduced expression of 
activating receptors, chemokine receptors, IFN-γ secretion, cytolytic activity 
and ADCC in response to TGF-β have all been reported (Wilson et al., 2011, 
Regis et al., 2017, Trotta et al., 2008). Moreover, inhibiting TGF-β has been 
shown to restore NK cell cytotoxicity in numerous tumour models (Otegbeye 
et al., 2018, Wilson et al., 2011). Multiple pathways have been identified to 
play a role in this inhibition, including the canonical TGF-β pathway and the 
mTOR pathway, but despite the obvious importance of TGF-β in NK cell 
regulation, the mechanisms that control this remain unclear. TGF-β was 
shown to inhibit CD16 mediated IFN-γ secretion from murine NK cells via a 
mechanism involving Smad3. The presence of TGF-β did not inhibit the 
phosphorylation of STATs, ERK or p38, but did suppress the expression of T-
BET, a positive IFN-γ regulator. Over expression of Smad3 could mimic TGF-
β effects, but interestingly, TGF-β exhibited inhibitory effects in smad3-/- cells, 
indicating that TGF-β mediated inhibition is not solely Smad3-dependent. 
Moreover, TGF-β was able to inhibit the expression of IFN-γ in Tbx21-/- cells 
(lacking T-bet), suggesting that TGF-β inhibits multiple pathways (Trotta et al., 
2008). In addition to multiple pathways, the activity of TGF-β was also shown 
to be modulated by kinetics. Whilst at shorter time-points TGF-β did not inhibit 
ADCC, the presence of TGF-β in longer cultures of NK cells (4 days) did inhibit 
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ADCC via downregulation of granzyme A and B proteins (Trotta et al., 2008). 
Another pathway that has been proposed to regulate TGF-β mediated 
inhibition is the mTOR pathway (Viel et al., 2016). In IL-15 stimulated murine 
NK cells, TGF-β displayed similar activities to that of the mTOR specific 
inhibitor, rapamycin. TGF-β reduced metabolic activity, inhibited the 
phosphorylation of mTOR associated proteins S6, 4EBP1 and Akt, reduced 
the expression of cytolytic proteins and inhibited degranulation in the 
presence of target cells. This study also highlighted similarities in protein 
expression between mTor-/- cells and cells with constitutive TGF-β signalling, 
further supporting the hypothesis that TGF-β inhibits the mTOR pathway (Viel 
et al., 2016). In contrast to this, a recent study in human primary NK cells 
showed distinct actions of TGF-β and rapamycin at different time-points 
(Zaiatz-Bittencourt et al., 2018). In accordance with the previous study by Viel 
et al., TGF-β significantly decreased the rate of OXPHOS and CD71 
expression in IL-2 or IL-12/IL-15 stimulated NK cells; however, the 
dependency on mTOR inhibition to achieve this differed between time-points. 
At shorter time points of 30 minutes and 1 hour, the presence of TGF-β did 
not inhibit the activity of mTOR (measured by phosphorylation of S6 and 
4EBP1) in IL-2 or IL-12/IL-15 stimulated NK cells. Interestingly, TGF-β did 
inhibit mTOR activity at later time-points (5 days), indicating that different 
pathways were targeted by TGF-β at specific time-points. Furthermore, the 
addition of a TGF-β receptor inhibitor to IL-2 + TGF-β stimulated NK cells 
restored functional and metabolic responses, suggesting that early TGF-β 
mediated inhibition is driven by the canonical TGF-β signalling pathway 
(Zaiatz-Bittencourt et al., 2018).  
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Multiple studies agree that TGF-β does not inhibit the phosphorylation 
of STAT proteins (Trotta et al., 2008, Viel et al., 2016, Sudarshan et al., 1999). 
In IL-15 stimulated NK cells, pSTAT5 expression remained unaltered in the 
presence of TGF-β or an anti-TGF-β antibody (Viel et al., 2016). In IL-12 and 
IL-2 activated NK cells and T cells, the presence of TGF-β did not inhibit the 
expression or phosphorylation or nuclear translocation of STAT4 and STAT5 
proteins, respectively (Sudarshan et al., 1999).  In this study, I have shown 
that TGF-β inhibits IL-10 mediated NK cell cytotoxicity in an mTOR and 
pSTAT3 independent manner, but the mechanism of this inhibition remains 
unknown. The fact that granzyme B expression is reduced in a STAT3 
independent manner by TGF-β suggests that other pathways may also be 
contributing to this upregulation, or that TGF-β inhibits STAT3 signalling 
further downstream. It is possible that TGF-β inhibits IL-10 via the canonical 
(Smad2/3 dependent) pathway at a point further downstream than the 
phosphorylation of STAT3. Cross-talk between Smad3 and STAT3 has been 
identified in several cell types and biological processes such as 
tumourigenesis, epithelial-mesenchymal-transition and T-cell differentiation 
(Tang et al., 2017, Itoh et al., 2017). Multiple direct and indirect mechanisms 
of reciprocal STAT3 and Smad3 negative regulation have been reported, 
including epigenetic modifications, inhibition of transcription factors and direct 
DNA binding (Itoh et al., 2017). In the context of T-cell differentiation, STAT3 
supresses Smad3 induced FoxP3 expression by binding the FoxP3 promoter 
region, but works as a co-activator with phosphorylated Smad3 to regulate 
RoRγt expression (Itoh et al., 2017). The interplay between STAT3 and 
Smads is highly complex and context-dependent, therefore, elucidating the 
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mechanism of TGF-β mediated inhibition in IL-10 activated NK cells will be 
challenging.  
Irrespective of TGF-β, experiments in this chapter show that STAT3 
inhibition suppresses IL-10 induced granzyme B expression and NK cell 
cytotoxicity. To investigate whether STAT3 activation mediated the same NK 
cell responses from another stimulus, I employed another NK cell activating 
cytokine known to signal via STAT3, IL-21 (Li et al., 2015, Denman et al., 
2012, Skak et al., 2008). IL-21 enhanced granzyme B expression and 
degranulation in a similar fashion to IL-10, suggesting that IL-21 and IL-10 are 
less potent than IL-15. Moreover, IL-21 mediated some activation 
mechanisms independently of others, i.e IL-21 enhanced cytotoxicity, but not 
CD69 expression.  
In contrast to this, several studies report that IL-21 modulates the 
expression of cell surface receptors including CD69 (Bhatt et al., 2015, Skak 
et al., 2008) and demonstrates pro-proliferative effects of IL-21 towards NK 
cells (Zeng et al., 2007, Skak et al., 2008, Denman et al., 2012).  However, 
species and cell types used in these studies differ and can provide conflicting 
evidence with regards to the role of IL-21. For instance, IL-21 induced 
proliferation in human NK cells, but not murine NK cells  (Brady et al., 2004) 
and two independent studies performed on human NK cells showed both 
upregulation and down regulation of NKG2D expression (Zhu et al., 2014, 
Burgess et al., 2006). Importantly, in human NK cells, the MAPK and PI3K 
pathways were found to mediate IL-21 induced NK cell proliferation, with 
inhibition of either pathways suppressing proliferation (Zeng et al., 2007). As 
these pathways are not known to be activated by IL-10 in NK cells, this 
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suggests that STAT3 is responsible for IL-21 and IL-10 induced cytotoxicity, 
and that these mechanisms are independently regulated. Additionally, IL-21 
has been shown to activate STAT1 and STAT5 pathways (to a weaker extent) 
that could potentially impact other activation mechanisms (Wan et al., 2015). 
Whether other additional pathways are required to induce IL-10 
mediated NK cytotoxicity remains unknown. Although steps have been taken 
in this study to try and determine other signalling pathways that may be utilised 
by IL-10, this study was not able to define these. Although STAT3 is the most 
prominent IL-10 activated pathway, (Verma et al., 2016) the potential 
involvement of other pathways at play in NK cells cannot be overlooked. The 
phosphorylated kinases ‘Proteome profiler’ was chosen as it allows for the 
simultaneous identification of 43 phospho kinases and 2 related total proteins, 
providing a time and cost-effective method to analyse multiple signalling 
pathways within one sample and eliminate donor dependent differences. 
However, the method used here did not indicate the involvement of other 
pathways in NK cells. Whilst there are benefits to using this approach, such 
as the ability to investigate multiple proteins in the same sample, there are 
also many limitations. The design of the membrane only allows for one time-
point to be compared. For this assay, cells were stimulated for 30 minutes as 
STAT3 has been shown to be phosphorylated at this time-point; however, this 
may not be optimal for all proteins investigated therefore may be more 
favourable to some proteins. Furthermore, this assay also requires a large 
amount of protein to overcome the sensitivity threshold and detect 
phosphorylation. Obtaining such large amounts of protein from primary 
lymphocytes acquired from a single donor can be difficult and costly. This 
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approach has led to inconclusive results, showing only marginal differences 
in kinase activity between untreated and IL-10 treated NK cells. Cytokines are 
known to activate multiple pathways including JAK/STAT, PI3K, and MAPK 
pathways (Ali et al., 2015, Nandagopal et al., 2014, Mishra et al., 2014), and 
the phosphorylation of so many kinases is not surprising. Interestingly, in this 
study I have shown that distinct pathways may be responsible for specific 
activation mechanisms. Blocking proliferation in IL-15 stimulated NK cells did 
not inhibit cytotoxicity, suggesting that the pathways mediating these 
responses are activated independently and are not associated. Similarly, in 
an IL-10 stimulated monocyte cell line, inhibition of the PI3K-mTOR pathway 
suppressed proliferation, but not anti-inflammatory effects (Crawley et al., 
1996). Simplistically, if one pathway regulates one activation mechanism, then 
it is possible that IL-10 does not activate several pathways in NK cells as it 
only enhances a subset of activation mechanisms. Nevertheless, cytokine 
signalling pathways are much more complex and further investigation of the 
pathways involved in IL-10 signalling is required to understand whether the 
pro-inflammatory effects of IL-10 are mediated solely via the STAT3 pathway. 
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Chapter 6 
Summary and conclusion 
6.1 Summary  
Primarily described as an anti-inflammatory cytokine (Couper et al., 2008, 
Verma et al., 2016), the pleiotropic activity of IL-10 is becoming clear in 
several cell types (Qayum et al., 2016, Polukort et al., 2016, Heine et al., 2014, 
Smith et al., 2018a, Mocellin et al., 2005). IL-10 has been shown to activate 
NK cells (and other immune cells) in several studies. However, many of these 
studies have been performed using NK cell-like cell lines that require cytokine 
stimulation to enable their proliferation and survival in long-term culture. In this 
study, I have investigated the potential of IL-10 to activate human primary NK 
cells. 
In this study, I have shown that IL-10 induces the phosphorylation of 
STAT3 in NK cells and subsequently enhances cytotoxicity. IL-10 stimulation 
upregulated granzyme B expression, NK cell degranulation and NK cell 
mediated target cell death. Additionally, I showed that IL-10 has an additive 
effect when used in combination with IL-15, inducing greater expression of 
granzyme B. Unlike IL-15, IL-10 did not induce the expression of lymphocyte 
activation marker CD69, or significantly alter the expression of key NK cell 
activating receptors NKG2D, DNAM1 or NKp30.  
IL-10 stimulation did not alter the production of IFN-γ; however, IL-10 
did increase the mRNA expression, suggesting that additional pathways are 
required to translate this into protein. Whether this secondary process is 
mRNA stabilisation through other signalling pathways, or changes in cellular 
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metabolism is undetermined. Recent studies highlight the importance of 
metabolic reprogramming in immune cells to enable optimal production of 
IFN-γ (Chang et al., 2013, Keating et al., 2016). Preliminary observations in 
this study revealed that IL-10 stimulation of NK cells did not result in metabolic 
changes, as determined by glucose uptake and cell growth, suggesting that 
this metabolic switch could be the secondary mechanism required for IFN-γ 
production. As mentioned previously, data regarding glucose uptake in this 
study should be interpreted cautiously given the recent data indicating that 2-
NBDG staining alone may not be a reliable indicator of glycolytic activity 
(Sinclair et al., 2020). Another possibility is the that IL-10 does not activate 
proteins that are required for mRNA stabilization. Typical inducers of IFN-γ, 
such as IL-12 and IL-18, stabilise IFN-γ mRNA through MAPK activation 
(Mavropoulos et al., 2005). This study was unable to define additional NK cell 
pathways regulated by IL-10; therefore, whether IL-10 activates pathways 
required for mRNA stabilisation remains to be determined. Additionally, IL-10 
has been shown to negatively regulate cytokine expression in macrophages 
by inducing the expression of tristetraprolin (TTP), a zinc finger binding protein 
that regulates mRNA expression by binding AU rich elements in mRNA and 
promoting degradation (Fu and Blackshear, 2016, Stumpo et al., 2010), 
highlighting another level of regulation. Further investigation into IL-10 
mediated cytokine production is required to understand the mechanisms that 
regulate this.  
Activation of NK cells with IL-10 occurred in a STAT3-dependent 
manner. Inhibition of STAT3 signalling, using a small molecule inhibitor that 
directly binds to STAT3 phosphorylation sites, completely abrogated IL-10 
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mediated enhancement of cytotoxicity. Interestingly, IL-10 mediated activation 
was susceptible to TGF-β inhibition in a STAT3-independent way; TGF-β did 
not inhibit the phosphorylation of STAT3 but did reduce the expression of 
granzyme B to basal levels and suppress the cytotoxicity of NK cells. Whether 
TGF-β prevents STAT signalling further downstream of pSTAT3 is yet to be 
defined. It is possible that TGF-β could inhibit the transcription factor activity 
of STAT3. Further investigations using a chromatin immunoprecipitation-
sequencing (ChIP-seq) approach would reveal if TGF-β inhibits the DNA-
binding of STAT3. Several Smad-dependent and Smad-independent 
pathways are downstream of TGF-β signalling (Papageorgis and 
Stylianopoulos, 2015); it would be interesting to explore whether transcription 
factors and coactivators/corepressors downstream of these pathways block 
DNA binding through shared binding sites, or bind promoter regions of STAT3 
regulated genes. Of course, it is also possible that TGF-β indirectly inhibits IL-
10 induced cytotoxicity through the expression of TGF-β mediated genes 
(Figure 28), for example by inducing the expression of transcriptional 
repressors or antagonists of IL-10 signalling. As previously mentioned, the 
potential cross-talk of Smads and STAT3 highlight the complexity of these 
signalling events and elucidating this interplay will be challenging.  
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Figure 28: Possible mechanisms of TGF-β mediated inhibition of IL-10 
activated NK cells 
TGF-β mediated inhibition of IL-10 mediated NK cell activation remains unknown. 
This schematic details possible mechanisms by which TGF-β potentially inhibits IL-
10; through the inhibition of unidentified pathways, transcriptional repression of 
STAT3 mediated genes/STAT3 binding, and through indirect mechanisms as a result 
of TGF-β induced gene expression.  
  
 - 154 - 
Results from this study clearly demonstrate that IL-10 and IL-15 
mediate distinct mechanisms of activation. IL-15 is a potent inducer of several 
effector pathways such as cytotoxicity, cytokine secretion, activating receptor 
expression and proliferation, whereas IL-10 selectively enhances cytotoxicity. 
In IL-15 stimulated NK cells, blocking entry to the cell cycle using a CDK4/6 
inhibitor, and therefore blocking proliferation, did not inhibit the IL-15-induced 
cytotoxicity of NK cells. This indicates that these activation pathways can be 
regulated independently of one another, and that different signalling pathways 
may be regulated individual mechanisms.   
Independent regulation of these mechanisms may be important when 
considering the environments that are likely to contain these cytokines. IL-15 
provides a strong survival and proliferation signal to NK cells, primarily from 
DCs in the LN and in response to infection (Ferlazzo et al., 2004, Wagstaffe 
et al., 2018, Wu et al., 2017, Lucas et al., 2007). However, prolonged 
activation with IL-15 is associated with NK cell exhaustion, resulting in the 
expression of checkpoint inhibitors LAG3 and PD-1 and genome-wide 
epigenetic changes that rendered them irresponsive to target cells (Merino et 
al., 2019). Furthermore, limiting the strength of IL-15 by inhibiting mTOR 
signalling was shown to rescue NK cell function, highlighting the role of mTOR 
in driving NK cell exhaustion (Felices et al., 2018).  
A possible benefit of the ‘restricted’ activation IL-10 induces is that it 
does not activate mTOR signalling or proliferation, therefore may be beneficial 
in environments that have limited nutrients, such as the tumour 
microenvironment (TME). Increasing metabolism to meet the biosynthetic 
demands of growth and proliferation requires an increased influx of nutrients. 
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Multiple cellular populations, including tumour cells and stromal cells, are 
competing for these and impaired immune cell activity in the TME is, at least 
partially, a result of nutrient competition. IL-10 is present in the tumour 
microenvironment and is therefore a potential site of interaction with NK cells. 
In this context, IL-10 could provide a mechanism of NK cell activation that is 
independent of increased nutrient uptake, and therefore not susceptible to 
inhibition by lack of nutrients. Indeed, others have shown anti-tumour activity 
of IL-10. In animal models, IL-10 has been shown to enhance tumour rejection 
by activating tumour-resident T cells, and T cells isolated from IL-10 treated 
tumours exhibit increased expression of granzyme B and IFN-γ (Mumm et al., 
2011, Emmerich et al., 2012). In a clinical trial evaluating the use of pegylated 
IL-10 in solid tumours, systemically administered IL-10 increased serum levels 
of pro-inflammatory cytokines IFN-γ and IL-18 whilst decreasing TGF-β 
(Naing et al., 2016). Furthermore, tumours being treated with mTOR inhibitors 
would be expected to have reduced T cell activity and IL-15 mediated NK cell 
activity. However, IL-10 (or IL-21) mediated NK cell activity might be retained 
under these conditions. 
IL-10 clearly plays an important role in the pathogenesis of many 
autoimmune and autoinflammatory diseases, but whether this role is solely 
immunosuppressive is up for debate. The pleiotropic activity of IL-10 is 
exemplified in rheumatoid arthritis, where overexpression of IL-10 contributes 
to immunosuppression but also enhances humoral immunity (Hernández-
Bello et al., 2017). Furthermore, the use of recombinant IL-10 to treat IBD has 
yielded poor results (Marlow et al., 2013), and in some cases, has enhanced 
inflammation (Tilg et al., 2002). IL-10, in this study and others, has shown 
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stimulating effects towards several immune cell populations and could 
therefore contribute to inflammation in disease, and promote anti-tumour 
immunity. However, whether the activity of IL-10 is anti-inflammatory or pro-
inflammatory is likely to be context and cell type-dependent. For example, 
although IL-10 activates NK cells when studied in isolation, the overall effect 
of IL-10 within the complex mixture of cells within the tumour 
microenvironment might be different, with IL-10 potentially inhibiting TNF 
release from monocytes and macrophage and reducing the overall pro-
inflammatory nature of the tumour microenvironment. Teasing apart such 
complex interactions will likely require the use of tumour-bearing IL-10R 
conditional knockout mouse models (e.g. using a floxed IL10R gene in 
conjunction with cell type expression of Cre recombinase).  
 
6.2 Future work 
Firstly, it must be noted that many of the experiments in this study do not show 
statistical significance, but rather ‘trends’ in the data. As this study investigates 
the cellular responses of individual human donor samples, rather than 
genetically identical cell lines or murine samples, the magnitude of variation 
between the samples can greatly impact the statistical significance of 
experiments. For instance, cells from healthy individuals will produce 
cytokines in response to certain stimuli, but the level of response may be 
higher/lower in one donor versus another (e.g. due to polymorphisms in genes 
encoding components of particular pathways). Therefore, it is important to 
increase the number of donors, repeat the assays and collect more data that 
can bolster the trends observed in this study. Moreover, further donors will 
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increase the power of the statistical tests, resulting in more robust, reliable 
data. 
Following on from the data presented in this study, identifying other 
pathways activated by IL-10 in NK cells would further our understanding of 
how this pleiotropic cytokine regulates NK cell activity, and help decipher the 
differences between IL-10 and IL-15 stimulation. Approaches such as 
phosphoproteomics have greater sensitivity than the proteome profiler used 
in this study and could therefore provide a more definitive list of pathways 
utilised by IL-10 to selectively enhance NK cell activities. Additionally, further 
research is required to understand the metabolic activity of NK cells following 
IL-10 stimulation. This study suggests that this is a key differentiator of IL-15- 
and IL-10-induced activation; therefore, techniques such as Seahorse 
analysis (measuring oxygen consumption rate [OCR] and extracellular 
acidification rate [ECAR]) could be employed to delineate metabolic changes 
induced by IL-10. This would be complemented by further analysis of proteins 
in the mTOR pathway. Lastly, it would be interesting to build upon the 
observation that TGF-β inhibited IL-10 induced NK cell activity independent of 
pSTAT3 inhibition. In addition to identifying other IL-10 activated pathways 
that may be targeted by TGF-β, comparing DNA-binding regions of pSTAT3 
with TGF-β-induced transcription factors (using ChIP-seq) would provide 
more information about this interaction. 
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6.3 Conclusion 
In conclusion, the data presented from this study indicates that IL-10 activates 
human primary NK cells in a mechanism that is distinct from IL-15. IL-10 
stimulation of NK cells results in STAT3-dependent upregulation of granzyme 
B expression and cytotoxicity. Unlike IL-15 stimulation that induces several 
activation mechanisms, such as proliferation, NK cell receptor expression, 
cytokine production and cytotoxicity, IL-10 stimulation selectively regulates a 
limited number of activation mechanisms. This selectivity may be useful in 
environments with limited nutrients, further investigation is required to 
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